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 ABSTRACT 
Background 
Drug-induced QT interval prolongation is associated with rare but life-
threatening ventricular arrhythmia and sudden death. To study ventricular arrhythmia 
and sudden cardiac death associated with QT prolongation in large databases, an 
accurate operational definition of this outcome is needed. Frequently prescribed 
macrolide and fluoroquinolone antibiotics are associated with torsades de pointes 
arrhythmia and sudden death. Due to the dose-dependent nature of the risk, 
concomitant use of multiple QT-prolonging drugs may pose a greater threat than 
singular use. Several observational epidemiologic studies suggest that azithromycin 
may have an increased risk of ventricular arrhythmia and sudden cardiac death. 
Meanwhile, other observational studies observed a relatively similar cardiac toxicity 
profile with azithromycin, as compared with no antibiotic use or other antibiotics. 
 
Objectives 
The purpose of the first manuscript in this dissertation is to identify operational 
definitions of arrhythmias and sudden death associated with QT prolongation used in 
retrospective database studies and to compare validation results between algorithms. 
The second manuscript focuses on quantifying the risk of cardiac adverse events 
related to concurrent concomitant use of QT-prolonging antibiotics and other drugs 
with similar pro-arrhythmic potential, and the risk factors associated with such events 
in a national, privately insured population in the United States. The third manuscript 
 seeks to assess the risk of ventricular arrhythmia and sudden death for macrolide and 
fluoroquinolone antibiotics in a national, commercially insured population in the 
United States and to compare these results with previously published observational 
studies. 
 
Methods 
In the first manuscript, we conducted a systematic literature review using 
PubMed to identify retrospective studies published between January 1, 2000 and 
August 31, 2016. We identified and reviewed studies of ventricular arrhythmia or 
sudden death associated with QT prolongation in large administrative databases. 
Validation methods and results were also extracted where validation was conducted. 
In the second manuscript, we performed a retrospective case-control study 
using an administrative health claims database from a large national insurer from 2011 
to 2013.  Cases of ventricular arrhythmia or sudden death due to QT prolongation 
were selected using a validated algorithm identified from the first manuscript. Four 
controls were matched to each case on age, sex, and region. Concomitant drug use was 
defined as overlapping durations of prescriptions of a QT-prolonging antibiotic and 
one other QT drug of interest. Odds ratios of risk factors and concomitant QT-
prolonging medication use were calculated using conditional logistic regression. 
In the third manuscript, a retrospective cohort study was conducted in the same 
administrative health claims database from a large national insurer from 2011 to 2013. 
The study cohort consisted of patients who filled an outpatient prescription for 
 macrolide and fluoroquinolone antibiotics, or amoxicillin. Amoxicillin episodes were 
1-to-1 matched to macrolide and fluoroquinolone episodes on propensity scores. 
Inpatient admissions or emergency department visits with a primary diagnosis of 
ventricular arrhythmia were assessed within 10 days and 30 days of the prescription 
dispensing. Cox proportional hazard models were used to estimate the hazard ratio. 
 
Findings 
In the first manuscript, several algorithms for identifying QT prolongation in 
large databases have been developed and validated. We found a common algorithm for 
QT prolongation that was validated in Medicaid, Medicare, and the Italian National 
Health Service data. We also found a validated operational definition for sudden death 
in Medicaid data.  
In the second manuscript, we found that concomitant and proximal use of QT-
prolonging antibiotics with other QT medications predicted ventricular arrhythmia or 
sudden death. 
In the third manuscript, azithromycin use and fluoroquinolone use was not 
associated with an increased cardiac risk compared with amoxicillin. Macrolide 
antibiotics, as a class, increased the risk of ventricular arrhythmia and sudden death in 
the 10 days following the prescription dispensing. 
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PREFACE 
Drug-induced QT interval prolongation is associated with rare but life-threatening 
ventricular arrhythmia and sudden death. Macrolide and fluoroquinolone antibiotics 
are considered to have a risk of QT prolongation despite conflicting results observed 
in retrospective studies. Meanwhile, the risk of concomitant use of multiple QT-
prolonging medications remains largely unknown. The purpose of this dissertation is 
to quantify the risk of ventricular arrhythmia and sudden death associated with 
macrolide and fluoroquinolone antibiotics, when exposed alone and in combination 
with other risk factors. 
 
Following the manuscript format, this dissertation consists of three manuscripts: 
Manuscript I. Algorithms used to identify arrhythmias and sudden cardiac death 
associated with QT prolongation in retrospective studies: a systematic 
literature review 
Manuscript II. Concomitant use of QT-prolonging medications and the risk of 
ventricular arrhythmia or sudden death 
Manuscript III. Risk of drug-induced ventricular arrhythmia and sudden death with 
QT-prolonging antibiotics
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INTRODUCTION 
DRUG-INDUCED QT PROLONGATION 
Drug-induced QT interval prolongation is associated with rare but life-
threatening ventricular arrhythmia and sudden death. Retrospective 
pharmacoepidemiologic studies are often conducted to assess risks of adverse events 
of medications.1,2 Based on such studies, QT prolongation has informed black box 
warnings and drug withdrawals.3 In 2013, azithromycin received a black box warning 
for potential risk of QT prolongation and fatal cardiac arrhythmias based on the 
findings of a large retrospective pharmacoepidemiologic study.4,5 In this era of big 
data, particularly for studies of rare outcomes, such as acute ventricular arrhythmia 
and sudden cardiac death associated with QT prolongation, an accurate operational 
definition of the outcome is needed. Physician review of an electrocardiogram is the 
gold standard for identifying QT prolongation, however it has limited use in 
retrospective database studies.6 First, it is often not available in large claims-based 
databases. Secondly, studies which rely on medical charts are often under-powered to 
study a rare outcome within a small study population.7 Lastly, electrocardiogram 
results are not able to capture arrhythmia and sudden death which occurred outside of 
the hospital setting. 
Macrolide and fluoroquinolone antibiotics are among the most frequently 
prescribed drugs that are associated QT prolongation, which can lead to torsades de 
pointes arrhythmia and sudden death.4,5,8-11 As dose-dependent risks have been 
identified from pharmacokinetic and pharmacodynamic research with QT-prolonging 
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medications, greater risk may exist with concomitant use of multiple QT-prolonging 
drugs.12,13 Torsades de pointes is also associated with other risk factors such as older 
age, female sex, hypokalemia, history of heart diseases, and renal impairment.14,15 
Numerous QT-prolonging drugs are metabolized by the same group of cytochrome 
isoenzymes (mostly CYP3A4).13,16 When exposed together, one drug will serve as the 
other’s metabolic enzyme inhibitors and cause drug accumulation which further 
increases the risk of drug-induced QT prolongation, a concentration-related event. In 
addition, another mechanism for increased risk would be the medications serving as 
each other’s synergist or antagonist.13,17 Some macrolides and fluoroquinolones are 
also known to have pharmacokinetic drug-drug interactions.18 Clarithromycin, 
erythromycin, and ciprofloxacin are all strong inhibitors of cytochrome P450 
isoenzymes.13 
All macrolide antibiotics are considered to have QT-prolonging potential. 
Azithromycin is not a CYP3A4 inhibitor, and was therefore considered to be safer 
than the rest of its class. However, several recent observational epidemiologic studies 
suggest that azithromycin may have an increased risk of ventricular arrhythmia and 
sudden cardiac death afterall.4,19,20 One retrospective cohort study published in 2012 
reported a higher risk of cardiovascular death associated with azithromycin compared 
with no antibiotic use in a Medicaid population.4 One year later, the United States 
Food and Drug Administration (FDA) issued a warning to urge healthcare 
professionals to consider potential cardiovascular risks when prescribing 
azithromycin.5 Subsequent observational studies among Veterans Affairs patients and 
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in the general population of Taiwan reported similar increased risks of serious 
arrhythmia, cardiovascular death, and all-cause mortality with azithromycin.19,20 
Alternatively, several observational studies reported a safer cardiac toxicity 
profile with azithromycin, as compared with no antibiotic use or other antibiotics 21-23 
In the Danish adult population, azithromycin use was not associated with an increased 
risk of cardiovascular death compared to either no antibiotic use or penicillin-V.22 
Another study among the general population of Ontario, Canada found that macrolide 
antibiotic use was not associated with a higher risk of ventricular arrhythmia 
compared with non-macrolide antibiotics.21 
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RESEARCH OBJECTIVES 
A number of pharmacoepidemiologic drug safety studies have sought to 
quantify the risk of drug-induced ventricular arrhythmia and sudden death. The 
algorithms identifying ventricular arrhythmia and sudden cardiac death associated 
with QT prolongation have varied between studies.19,20,24-26 Identifying a validated 
algorithm is needed in order to have an accurate definition of this outcome and for 
comparability between studies. Interactions among QT-prolonging agents are well-
studied in the field of pharmacokinetics and pharmacodynamics but are less well-
studied in the field of pharmacoepidemiology. Concomitant use of multiple QT-
prolonging drugs may pose a greater threat than singular use. Conflicting cardiac 
safety profiles for QT-prolonging antibiotics, including azithromycin, have been 
observed in different populations worldwide. These populations varied in age, social 
economic status, and disease burden.  
Based on these unanswered questions, this dissertation has three objectives 
related to drug-induced QT interval prolongation, namely: 
1. To identify the operational definitions of arrhythmias and sudden death 
associated with QT prolongation used in retrospective database studies and compare 
validation results between algorithms. 
2. To quantify the risk of cardiac adverse events related to concomitant use of 
QT-prolonging antibiotics and other drugs with similar pro-arrhythmic potential, and 
other risk factors associated with such events in a national, privately-insured 
population in the United States.  
   5 
 
3. To assess the risk of ventricular arrhythmia and sudden death associated with 
macrolide and fluoroquinolone antibiotics in a national, commercially insured 
population in the United States and compare these results with previously published 
observational studies. 
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ABSTRACT 
Drug-induced QT prolongation can lead to ventricular arrhythmia and sudden cardiac 
death. As ventricular arrhythmia and sudden cardiac death are rare events, large 
administrative databases can be used to inform pharmacoepidemiologic drug safety 
studies. In order to compare event rates between studies, validated operational 
definitions of these events are needed. We conducted a systematic literature review in 
PubMed to identify diagnosis code algorithms for arrhythmias and sudden cardiac 
death. Twenty-two studies were included in the review. For arrhythmias, a common 
operational definition was identified in 23% of the reviewed studies (n=5), with an 
average positive predictive value (PPV) of 85% from hospital stays and emergency 
visits. For sudden cardiac death, codes for cause of death was used in 14% of studies 
(n=3), with an average PPV of 88%. Further validation of a common International 
Classification of Diseases, 10th Edition (ICD-10) algorithm is needed for each event. 
In conclusion, researchers should utilize a common, validated algorithm, such as the 
one identified in our review to operationally define these events to ensure 
comparability between new research and the existing literature.  
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BACKGROUND 
Unexpected sudden death is rare, with an estimated incidence ranging from 50 
to 100 per 100,000 individuals per year in Europe and North America.1,2 Acute 
ventricular arrhythmia may account for over 80% of sudden cardiac deaths.3 
Retrospective pharmacoepidemiologic studies are used to assess risks attributed to 
drug exposures.4,5 Based on such studies, QT prolongation has informed black box 
warnings and drug withdrawals.6 Terfenadine and cisapride were withdrawn in the 
United States (US) in 1998 and 2000 respectively, due to their association with QT 
prolongation and ventricular arrhythmia.7,8 More recently, in 2013, azithromycin 
received a black box warning for potential risk of QT prolongation and fatal cardiac 
arrhythmias based on the findings of a large retrospective pharmacoepidemiologic 
study.9,10  
In this era of big data, particularly for studies of rare outcomes, such as acute 
ventricular arrhythmia and sudden death associated with QT prolongation, an accurate 
operational definition of the outcome is needed. Physician review of an 
electrocardiogram (ECG) is the gold standard for identifying QT prolongation, 
however it has limited use in retrospective database studies.11 First, ECG results are 
often not available in large databases. Further, a study identifying events by manual 
medical record review of ECGs and physician notes would likely be under-powered to 
quantify the exposure-outcome relationship. Lastly, ECG results for acute ventricular 
arrhythmia and sudden death which occurred outside of the hospital will not be 
available, and would result in underestimation of these events.  
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A number of retrospective pharmacoepidemiologic drug safety studies have 
sought to quantify the association between these rare outcomes and different 
medication exposures, however the algorithms identifying ventricular arrhythmia and 
sudden death associated with QT prolongation have varied between studies.12-16 
Further the performance of these varying algorithms has not been compared. The 
objective of this systematic literature review was to identify the operational definitions 
of arrhythmias and sudden death associated with QT prolongation used in 
retrospective database studies and compare validation results between algorithms.  
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METHODS 
A systematic literature review in the PubMed electronic databases was 
conducted to identify retrospective studies from peer-reviewed journals. A pre-
determined search strategy developed by Mini-Sentinel researchers (Table 1.1) was 
used to select qualifying studies published between January 1, 2000 and August 31, 
2016.17 This literature review was limited to studies in humans and published in 
English. Other inclusion criteria were: retrospective studies in large administrative 
databases; studies that identified ventricular arrhythmia and sudden death associated 
with QT prolongation; studies that only defined QT prolongation with ECG. Titles and 
abstracts of studies identified by the search were screened against the inclusion 
criteria. Qualifying or uncertain studies from title and abstract review underwent 
further full-text review for selection. References of selected studies were also 
examined for inclusion. Data extracted included operational definitions and 
administrative codes used for identifying ventricular arrhythmia and sudden death 
associated with QT prolongation. Other aspects of study design including publication 
year, study setting and population, and sample size, were also collected. Validation 
methods and results were also extracted where validation was conducted. 
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RESULTS 
The search strategy identified 1,237 studies. After title and abstract review, 57 
studies were selected for full-text review, after which, 22 (38.6%) studies were 
selected for inclusion. The literature search, review, and selection process was 
demonstrated in Figure 1.1 with results of each step in Table 1.1. 
The characteristic of included studies is showed in Table 1.2. Half of the 
included studies were published after 2012, which was the year a previous literature 
review of validated methods for identifying ventricular arrhythmia was published.17 
Approximately half of the studies (n=12, 55%) were conducted in US populations, 
using Medicare or Medicaid data (n=9, 41%),8,9,12,13,18-22 commercial health plan data 
(n=2, 9%),7,16 or Veterans Health Administration data (n=1, 4.5%).15 The remaining 
studies (n=10, 45%) were conducted in: European databases (n=5, 23%) from the 
Netherlands,23 France,24 Italy,25 Denmark,26,27 and Sweden27; the Taiwanese National 
Health Insurance Research Database (n=3, 14%)14,28,29; and Canadian provincial 
databases (n=2, 9%).30,31 International Classification of Diseases, Ninth Revision 
(ICD-9) codes were used to identify cardiac arrhythmias and/or sudden cardiac deaths 
in 17 studies (77%),7-9,12,13,15,16,18-23,25,28,29,31 while 4 studies (18%) used International 
Classification of Diseases, Tenth Revision (ICD-10) codes,24,26,27,30 and 1 study (4.5%) 
used both ICD-9 and ICD-10 codes. All studies used diagnosis codes for event 
definitions and no procedure codes were used. 14  
ICD-9 diagnosis codes for arrhythmias were used in 15 out of 22 studies 
(68%). Shared by 5 studies,8,13,19,20,25 the most common algorithm (Table 1.3) used 
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hospital stays and ED visits for ventricular arrhythmia to identify QT prolongation. 
Validation was conducted in three of these studies by review of the medical record. 
When limited to principle diagnosis, this algorithm had a positive predictive value 
(PPV) of 80% and 94% for hospitalization diagnosis and ED diagnosis respectively in 
Medicaid and Medicare data and the overall PPV was 85%.13 Other validation studies 
in a Medicaid and Medicare combined population and in an Italian population showed 
a PPV of 85% and 73%, respectively.13,25 One variation of the algorithm (excluded 
ICD-9 code 798) was used by one of the Taiwanese studies and a 
Medicaid/HealthCore study but neither study evaluated the validation of the 
algorithm.22,28 Another variation (only included ICD-9 codes 427.1, 427.4, and 427.5) 
of this algorithm in a study using Medicare data demonstrated a PPV of 93%, as 
validated by medical record review.18  
  The next most common algorithm for arrhythmias was utilized in two studies, 
one from the Netherlands and the other from Canada.23,31 The algorithm identified QT 
prolongation from hospital stays with primary diagnoses of arrhythmias. Only the 
Dutch study validated the algorithm, where a review of medical records was used to 
verify the ICD-9 codes used for ventricular arrhythmia and cardiac arrest (PPV 82%) 
and ICD-9 codes for unspecified cardiac arrhythmias (PPV 10%).23 The five other 
studies each used a different algorithm to identify potential QT prolongation. The 
Harvard community health plan study used select ICD-9 subcodes under 426, 427, 
429, 780, and 785 from hospital stays and ED visits, with a low PPV of 4%.16 The 
United Healthcare study included office visits and inpatient stays with diagnoses of 
arrhythmic events (ICD-9 codes 426.x, 427.x) but this approach also had low a PPV of 
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10% based on a review of medical records.7 Three other algorithms were used in two 
of the Taiwanese studies and the Veterans Health Administration study and none of 
these studies validated their operational definition.14,15,29  
 ICD-10 diagnosis codes for acute ventricular arrhythmia were used in 3 studies 
(13.6%). A French study,24 a Denmark-Sweden bi-national study,27 and one of the 
Canadian studies30 each used a different algorithm for identifying QT prolongation in 
hospital stays or ED visits. The Canadian study used ICD-10 codes I47.2 and I49.0 
and a manual chart review was conducted in 202 charts resulting in a PPV of 92%.30 
The French study used ICD-10 codes I46.1, I47.2, and I49.0 from hospital discharge 
summaries. In comparison with ECG records, this algorithm had a PPV of 60%.24 The 
bi-national study used ICD-10 codes I47.2, I49.0, I49.3, I46.0, I46.1, I46.9, R96.0, and 
R96.1 and no validation was conducted.27  
Besides arrhythmias, sudden death has also been used to identify QT 
prolongation in large retrospective databases, with both ICD-9 and ICD-10 codes. 
ICD-9 codes for sudden death were used in 4 of the 22 (18.2%) reviewed studies. An 
algorithm used in the Tennessee Medicaid study to identify sudden death associated 
QT prolongation was also used in 2 other studies (Table 1.4).12 This algorithm 
excluded deaths with terminal institutional stays or terminal procedures inconsistent 
with unresuscitated cardiac arrest. A series of ICD-9 codes for causes of death were 
used to define plausible sudden cardiac death. This algorithm was validated by 
medical record review in a general Medicaid population and in opioid users, and the 
PPV of this algorithm was 87% and 88%, respectively.12,21 Another algorithm used by 
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one of the Taiwanese studies defined the study outcome as unspecific cardiovascular 
death (ICD-9 codes 401-449) and this algorithm was not validated.14  
The Danish study and one of the Taiwanese studies identified death from 
cardiovascular causes using ICD-10 codes (n=2, 9.1%).14,26 Codes used in the Danish 
study were I00-I99 (diseases of the circulatory system) and R96.x (other sudden death, 
cause unknown).26 Codes used in the Taiwanese study were I10-I79 (hypertensive 
diseases, ischemic heart diseases, pulmonary heart disease and diseases of pulmonary 
circulation, other forms of heart disease, and cerebrovascular diseases).14 Neither 
study performed validation of their algorithms. 
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DISCUSSION 
We identified common, validated operational definitions for identifying 
arrhythmias and sudden death associated with QT prolongation in large retrospective 
database studies. The most common algorithm for ventricular arrhythmia (Table 1.3) 
and sudden death (Table 1.4) had an average PPV of 85% and 88%, respectively. 
These two algorithms were validated in various patient populations, including 
Medicaid and Medicare, administrative claims databases, and several European and 
Canadian databases. For ICD-9 arrhythmias algorithms, the PPV was highest when the 
limited to principle diagnoses and addition less specific subcodes decreases the 
PPV.7,8 Though one ICD-10 algorithm for arrhythmias was found to have a high PPV, 
this algorithm has not been used or validated in another database.30  The sole ICD-9 
sudden death algorithms had a high PPV for identifying QT prolongation among 
patients with a low risk of sudden cardiac death.12  
Our study has a few limitations. Firstly, the literature search terms might miss 
some other studies that also identified QT prolongation in retrospective databases. We 
attempted to address this limitation by examining the references of reviewed studies 
for additional studies and found no additional eligible studies in the references. 
Secondly, the true incidence of QT prolongation is unknown as QT prolongations can 
occur without noticeable symptoms.32,33 As such, validation studies could only 
calculate the PPV but not sensitivity or specificity. However, as a PPV is the 
proportion of true positive in tested positive, validated algorithms with high PPV may 
accurately identify cases captured in large retrospective databases.  
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CONCLUSION 
A common, validated algorithm for QT prolongation related arrhythmias was 
identified and validated in Medicaid, Medicare, and the Italian National Health 
Service data, as was a validated operational definition for sudden death in Medicaid 
data. Consistency between studies is necessary for establishing causal relationships 
between medications and rare adverse events, such as prolonged QT associated 
arrhythmias and sudden cardiac death. As such, to ensure comparability between new 
research and the existing literature, researchers should utilize a common, validated 
algorithm, such as the one identified in our review, to operationally define these 
events.  
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Table 1.1 Literature search strategy and number of searched studies 
 Search terms 
Limits: Humans; English; publication date between 2000/01/01 to 
2016/08/31 
Number of 
results 
#1 "Pharmaceutical preparations/adverse effects"[Mesh] OR 
"Pharmaceutical preparations/contraindications"[Mesh] OR 
"Pharmaceutical preparations/poisoning"[Mesh] OR "Pharmaceutical 
preparations/therapeutic use"[Mesh] OR "Pharmaceutical 
preparations/toxicity"[Mesh] OR "Pharmaceutical 
preparations/therapy"[Mesh] OR "Pharmaceutical 
preparations/analysis"[Mesh] OR "Chemical actions and uses/adverse 
effects"[Mesh] OR "Chemical actions and 
uses/contraindications"[Mesh] OR "Chemical actions and 
uses/poisoning"[Mesh] OR "Chemical actions and uses/therapeutic 
use"[Mesh] OR "Chemical actions and uses/toxicity"[Mesh] OR 
"Chemical actions and uses/therapy"[Mesh] OR "Chemical actions and 
uses/analysis"[Mesh] OR "Chemical actions and 
uses/epidemiology"[Mesh] OR "Drug toxicity"[Mesh] OR "Diseases 
Category/chemically induced"[Mesh] OR "Diseases Category/drug 
therapy"[Mesh] OR "Diseases Category/epidemiology"[Mesh] OR 
"Validation Studies"[pt] OR "Validation Studies as Topic"[Mesh] OR 
"Sensitivity and Specificity"[Mesh] OR "Predictive Value of 
Tests"[Mesh] OR "Reproducibility of Results"[Mesh] OR “Predictive 
Value”[tw] 
2,359,927 
#2 "Premier"[All] OR "Solucient"[All] OR "Cerner"[All] OR 
"Ingenix"[All] OR "LabRx"[All] OR "IHCIS"[All] OR 
"marketscan"[All] OR "market scan"[All] OR "Medstat"[All] OR 
"Thomson"[All] OR "pharmetrics"[All] OR "healthcore"[All] OR 
"united healthcare"[All] OR "UnitedHealthcare"[All] OR "UHC"[All] 
OR "GPRD"[All] OR "general practice research database"[All] OR 
"Research Database"[All] OR "Group Health"[All] OR "HCUP"[All] 
OR ("Healthcare Cost"[All] AND "Utilization Project"[All]) OR 
("Health Care Cost"[All] AND "Utilization Project"[All]) OR 
"MEPS"[All] OR "Medical Expenditure Panel Survey"[All] OR 
"NAMCS"[All] OR "National Hospital Ambulatory Medical Care 
Survey"[All] OR "National Ambulatory Medical Care Survey"[All] OR 
"NHIS"[All] OR "National Health Interview Survey"[All] OR 
"Kaiser"[All] OR "HMO Research"[All] OR "Health Maintenance 
Organization"[All] OR "HMO"[All] OR "Cleveland Clinic"[All] OR 
"Lovelace"[All] OR "Department of Defense"[All] OR "Henry 
Ford"[All] OR ("Denmark"[All] AND "Epidemiology"[All]) OR "i3 
Drug Safety"[All] OR "i3"[All] OR "Aetna"[All] OR "Humana"[All] 
OR "Wellpoint"[All] OR "IMS"[All] OR "Intercontinental Marketing 
Services"[All] OR "IMS Health"[All] OR "Geisinger"[All] OR "GE 
Healthcare"[All] OR "MQIC"[All] OR "PHARMO"[All] OR "Institute 
for Drug Outcome Research"[All] OR "Pilgrim"[All] OR "Puget 
Sound"[All] OR "Regenstrief"[All] OR "Saskatchewan"[All] OR 
"Tayside"[All] OR "MEMO"[All] OR "Medicines Monitoring 
Unit"[All] OR "Veterans Affairs"[All] OR "Partners Healthcare"[All] 
OR "Mayo Clinic"[All] OR "Rochester Epidemiology"[All] OR "Indiana 
521,010 
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Health Information Exchange"[All] OR "Indiana Health"[All] OR 
"Intermountain"[All] OR "THIN"[All] OR “The health improvement 
network"[All] OR "blue cross"[All] OR "health partners"[All] OR 
"health plan"[All] OR "health services"[All] OR "Nationwide Inpatient 
Sample"[All] OR "National Inpatient Sample"[All] OR "medicaid"[All] 
OR "medicare"[All] OR "MediPlus"[All] OR "Outcome 
Assessment"[All] OR "insurance database"[All] OR "insurance 
databases"[All] OR "Data Warehouse"[All] OR "ICD-9"[All] OR 
“international statistical classification"[All] OR “international 
classification of diseases"[All] OR "ICD-10"[All] OR "Database 
Management Systems"[Mesh] OR "Medical Records Systems, 
Computerized"[Mesh] OR "CPT"[All] OR "Current procedural 
terminology"[All] OR "drug surveillance"[All] OR (“claims”[tw] AND 
“administrative”[tw]) OR (“data”[tw] AND “administrative”[tw]) OR 
"Databases, Factual"[Mesh] OR "Databases as topic"[Mesh] OR 
"Medical Record Linkage"[Mesh] OR "ICD-9-CM"[All Fields] OR 
"ICD-10-CM"[All Fields]  
#3 "Clinical Trial"[pt] OR "Editorial"[pt] OR "Letter"[pt] OR "Meta-
Analysis"[pt] OR "Randomized Controlled Trial"[pt] OR "Clinical Trial, 
Phase I"[pt] OR "Clinical Trial, Phase II"[pt] OR "Clinical Trial, Phase 
III"[pt] OR "Clinical Trial, Phase IV"[pt] OR "Comment"[pt] OR 
"Controlled Clinical Trial"[pt] OR "case reports"[pt] OR "Clinical Trials 
as Topic"[Mesh] OR "double-blind"[All] OR "placebo-controlled"[All] 
OR "pilot study"[All] OR "pilot projects"[Mesh] OR "Review"[pt] OR 
"Prospective Studies"[Mesh] 
2,995,791 
#4 "Arrhythmias, Cardiac"[Mesh:NoExp] OR "Brugada 
Syndrome"[Mesh:NoExp] OR "Cardiac Complexes, Premature"[Mesh] 
OR "CommotioCordis"[Mesh:NoExp] OR "Heart Block"[Mesh] OR 
"Long QT Syndrome"[Mesh] OR "Parasystole"[Mesh] OR "Pre-
Excitation Syndromes"[Mesh] OR "Tachycardia"[Mesh] OR 
"Ventricular Fibrillation"[Mesh] OR "Ventricular Flutter"[Mesh] OR 
"Death, Sudden, Cardiac"[Mesh] OR "Torsades de Pointes"[Mesh] OR 
"Heart Arrest"[Mesh] OR "Tachycardia, Supraventricular"[Mesh] 
55,302 
#5 Search #1 AND #2 182,942 
#6 Search #5NOT OTHERWISE SPECIFIED #3  120,606 
#7 Search #6 AND #4 1,237 
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Table 1.3 The most common ICD-9 diagnosis codes for ventricular arrhythmias 
related to QT prolongation  
ICD-9 code* Code description 
427.1 Paroxysmal ventricular tachycardia 
427.4 Ventricular fibrillation and flutter 
427.41 Ventricular fibrillation 
427.42 Ventricular flutter 
427.5 Cardiac arrest 
427.9 Cardiac dysrhythmia, not otherwise specified 
798+ Sudden death, cause unknown 
798.1 Instantaneous death 
798.2 Death occurring in less than 24 hours from onset of 
symptoms, not otherwise explained 
ED = Emergency Department; ICD = International Classification of Diseases 
 
* Algorithm used by 5 reviewed studies8,13,19,20,25 
+ A more specific algorithm (without the general code 798) was used in 2 other studies22,28 
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Table 1.4 The most common ICD-9 codes for sudden death related to QT prolongation 
ICD-9 code* Code description 
401.9 Essential hypertension, not otherwise specified 
402.9 Hypertensive heart disease, not otherwise specified 
410 Myocardial infarction 
411 Other acute/subacute ischemic heart disease 
414.0 Coronary atherosclerosis 
414.8 Chronic ischemic heart disease, other 
414.9 Chronic ischemic heart disease, unspecified 
425.4 Primary cardiomyopathy, not otherwise specified 
427.1 Paroxysmal ventricular tachycardia 
427.4 Ventricular fibrillation and flutter 
427.5 Cardiac arrest 
427.9 Cardiac dysrhythmia, not otherwise specified 
429.2 Cardiovascular arteriosclerosis  
429.9 Cardiovascular disease, not otherwise specified 
440.9 Atherosclerosis, generalized and unspecified 
798.9 Unattended death 
ICD = International Classification of Diseases 
* Algorithm used by 3 reviewed studies9,12,21 
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Figure1.1 Flow chart of literature search and selection process 
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ABSTRACT 
Background: A major drug safety concern associated with hundreds of medication is 
the potential for QT interval prolongation. However, the real-world impact of taking 
multiple medications with QT prolongation potential has not been widely studied since 
events related to this adverse event are rare. 
Objective: To investigate the risk for ventricular arrhythmia or sudden death 
associated with concomitant prescriptions of QT-prolonging drugs. 
Methods: A retrospective case-control study was conducted using an administrative 
health claims database from a large national insurer. Cases of ventricular arrhythmia 
or sudden death between 2011 and 2013 were matched with four controls of the same 
age, sex, and geographic region. Concomitant drug use was defined as exposure to an 
antibiotic with QT-prolonging potential and one other medication carrying the same 
risk with overlapping durations of prescriptions. Proximal drug use was defined as a 
gap no larger than 15 days between durations of a QT-prolonging antibiotic and one 
other QT-prolonging drug. Adjusted odds ratios were estimated for concomitant and 
proximal QT-prolonging medication use and other risk factors using conditional 
logistic regression. 
Results: We identified 4,612 cases of ventricular arrhythmia and sudden death and 
18,448 controls. Concomitant QT medication use was a strong predictor of ventricular 
arrhythmia and sudden death (adjusted odds ratio [aOR] 2.91; 95% confidence interval 
[CI] 1.19-7.08). Proximal QT medication use was also predictive of ventricular 
arrhythmia and sudden death (aOR 2.20; 95% CI 1.23-3.40). Our study confirmed 
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several known predictors, such as hypokalemia and cardiac arrhythmia, and also 
identified several new predictors, including higher Charlson Comorbidity Index. Risk 
of ventricular arrhythmia or sudden death increased as the number of exposures to QT 
medications increased in the 10 days prior to the event. 
Conclusion: In this privately-insured adult population, concomitant and proximal use 
of QT-prolonging antibiotics with other QT medications was predictive of ventricular 
arrhythmia or sudden death. In clinical practice, exposure to multiple QT-prolonging 
medications should be avoided or closely monitored when necessary. 
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BACKGROUND 
Macrolide and fluoroquinolone antibiotics are among the most frequently 
prescribed drugs that are associated QT prolongation, which can lead to torsades de 
pointes (TdP) arrhythmia and sudden death.1-6 The risk is dose-dependent, therefore 
concomitant use of multiple QT-prolonging medications (QT medication) may pose a 
greater threat than singular use. TdP is also associated with other risk factors such as 
older age, female sex, hypokalemia, history of heart diseases, and renal impairment.7,8  
Pharmacokinetic interactions among QT-prolonging agents are well-studied. 
Numerous QT drugs are metabolized by the same group of cytochrome isoenzymes 
(mostly CYP3A4).9,10 When exposed together, one drug will serve as the other’s 
metabolic enzyme inhibitor and cause drug accumulation which further increases the 
risk of drug-induced QT prolongation, a concentration-related event. In addition, 
pharmacodynamics is another mechanism for increased risk as the medications can 
serve as each other’s synergist or antagonist.9,11 Some macrolides and 
fluoroquinolones are also well known for pharmacokinetic drug-drug interactions.12 
Clarithromycin, erythromycin, and ciprofloxacin are all strong inhibitors of 
cytochrome P450 isoenzymes (CYPs).9 Thus, their safety profile may outweigh any 
potential benefits when used concomitantly, especially if one of the drugs is prescribed 
in high doses. When such interactions are suspected, available therapeutic alternatives 
should be considered in order to reduce the risk of ventricular arrhythmia and sudden 
death.13 
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This study sought to quantify predictors of ventricular arrhythmia and sudden 
death associated with drug-induced QT prolongation, including concomitant exposure 
to one QT-prolonging antibiotic (QT antibiotic) and one other QT-prolonging 
medication (other QT medication) with similar pro-arrhythmic potential, in a national, 
privately-insured population.  
  
 38 
 
METHODS 
To achieve the study objective, a retrospective matched case-control study was 
conducted to assess risk factors of ventricular arrhythmia and sudden death, including 
concomitant QT medication exposures. 
Data source 
We utilized the de-identified Optum Clinformatics™ DataMart database 
(OptumInsight, Eden Prairie, MN) for this study, which is an administrative health 
claims database from a large national insurer. We utilized member eligibility files, 
medical claims, confinement claims, and pharmacy claims to conduct this study. 
Study population 
From the data source, we identified cases of severe ventricular arrhythmias 
and/or sudden death from January 1, 2011 to December 31, 2013. The cases were 
defined as having a primary hospitalization diagnosis or first-listed emergency 
department (ED) visit for ventricular arrhythmia, cardiac arrest, sudden death, or 
instantaneous death (International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] codes: 427.1, 427.4, 427.41, 427.42, 427.5, 798, 798.1, and 
798.2). This outcome definition was validated in previous studies with positive 
predictive values (PPVs) of over 80%.14,15 Four controls were matched to each case by 
exact age in years, sex, and geographic region of the patient. 
The diagnosis date was defined as the case index date (t0) and each matched 
control was assigned their case’s index date. Included patients were at least 18 years of 
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age on index date and had at least 365 days of continuous enrollment prior to the index 
date to identify relevant predictors, including medical history and previous medication 
exposures. We excluded patients that had congenital cardiovascular anomalies since 
these patients had a higher baseline risk for sudden death compared to the rest of the 
population. Patients with unknown age or sex were also excluded from the study. 
Independent Predictors 
Medications with risk of QT prolongation were identified from pharmacy 
claims, and categorized by class: QT antibiotics (macrolides or fluoroquinolones), 
antidepressants, antipsychotics, antihistamines, and antiarrhythmics.16-18 The list of 
medications assessed can be found in Appendix A. Prescription duration was 
calculated from the fill date and days of supply. A patient was considered having 
concomitant drug exposure if the patient: 1) received any QT antibiotic 30 days prior 
to index date, 2) also received other QT medications (antidepressants, antipsychotics, 
antihistamines, or antiarrhythmics), and 3) the prescriptions of the QT antibiotic and 
the other QT medication overlapped by at least one day.19 In a sensitivity analysis, 
rather than concomitant use, a proximal use definition of within ± 15 days was 
applied. We also identified the number of QT medications used by each patient 10 
days prior to the index date. The value was categorized as 0, 1, 2, and ≥3 to assess the 
risk of multiple QT medications in that time frame, regardless of overlap. 
Other potential predictors included the Charlson Comorbidity Index, calculated 
from medical and confinement claims 365 days prior to the index date.20,21 We also 
assessed other known risk factors for ventricular arrhythmia or sudden death in the 
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365 days prior to the index date.7,12,22,23 Due to potential cardiac risks, clarithromycin, 
erythromycin, ciprofloxacin, and levofloxacin dose adjustment is recommended for 
patients with hypokalemia and renal impairment.24 Therefore, the effect of 
hypokalemia and chronic kidney disease were assessed as risk factors in our study. 
Furthermore, relevant cardiac comorbidities were identified from diagnosis (Appendix 
A).7,23,25 
Statistical Analysis  
For direct comparisons between cases and controls, the Pearson Chi-square 
(χ2) test was utilized for categorical variables. For categorical variables that did not 
meet assumptions for χ2 (n <5), the Fisher’s exact test was used. T-test was used for 
comparing continuous normally distributed demographic variables. Conditional 
logistic regression was used to identify independent predictors associated being a case 
using an iterative, manual backward elimination approach.26 We used univariable 
analyses to select potential significant independent predictors that had a p-value < 
0.05. Selected variables were tested for collinearity and correlated variables were 
selected based on clinical significance. Then a multivariable conditional logistic 
regression model containing all covariates identified in the univarible analyses was fit 
to assess the importance of each covariate and non-significant variables (p-value > 
0.05) were removed one-by-one until only significant predictors remained in the 
model. Adjusted odds ratios (AORs) and associated 95% confidence intervals (CI) 
were reported from the final conditional logistic regression model.  
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All statistical analyses were performed using SAS Enterprise Guide, version 
7.1 (SAS Institute Inc., Cary, NC, USA). This study was reviewed and approved as 
exempt by the University of Rhode Island’s Institutional Review Board.  
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RESULTS 
We identified 4,612 patients who had ventricular arrhythmia or sudden death 
from January 1, 2011 through December 31, 2013 and 18,448 controls matched on 
age, sex, and geographic region. The matched cases and controls had identical 
distributions for the matching variables (Table 2.1). The comorbidity burden in the 
cases was higher than the controls. The mean Charlson comorbidity index was 2.8 
(standard deviation [SD] 3.1) among cases and 0.5 (SD 1.3) among controls. Cases 
were significantly (p<0.0001) more likely to have a history of cardiovascular diseases 
than controls as well as myocardial infarction (10.3% cases, 1.1% controls), 
congestive heart failure (31.6% cases, 2.5% controls), cardiac arrhythmia (40.0% 
cases, 5.3% controls), and heart valve disease (21.7% cases, 3.3% controls), diabetes 
with complications (11.6% cases, 2.0% controls) and hypokalemia (7.4% cases, 0.9% 
controls). 
In the study population, 1,862 patients had exposure to QT-prolonging 
antibiotics 30 days prior to the event date. Among these patients, 404 were exposed to 
macrolide antibiotics and 1,458 were exposed to fluoroquinolone antibiotics, while 
none were exposed to both classes of medications in that 30 day period. Only 37 
patients in our study population had concomitant exposures (Table 2.1). Proximal QT-
prolonging medication use, where medication durations occurred within 15 days of 
each other, was observed in 81 patients. Among the 23,060 patients included in this 
study, 20,461 (88.7%) did not use any QT-prolonging medications in the 10 days prior 
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to index date, while 1,807 (7.8%) patients used one QT-prolonging medication, 619 
(2.7%) used two, and 173 (0.8%) used three or more. 
Predictors 
Patients with concomitant QT-prolonging medication use (QT antibiotic + 
other QT medication) had a 3-fold increase in the odds of ventricular arrhythmia or 
sudden death (adjusted odds ratio [aOR] 2.91; 95% CI 1.19-7.08, Table 2.2). Proximal 
QT-prolonging medication use within 15 days was also a strong predictor of 
ventricular arrhythmia or sudden death (aOR 2.2, 95% CI 1.23-3.99, Table 2.3). The 
strongest predictors of ventricular arrhythmia or sudden death for both concomitant 
(Table 2.2) and proximal (Table 2.3) use were the Charlson Comorbidity Index and a 
history of cardiac arrhythmias. Similar predictors of comorbidity burden and specific 
cardiac conditions were identified when evaluating concomitant or proximal QT-
prolonging medication exposures. History of palpitation, congestive heart failure, 
chronic pulmonary disease, cardiomyopathy, and hypokalemia were also identified as 
independent predictors in the multivariable models. Patients who had diabetes without 
complications, myocardial infarction, mild liver disease, chronic pulmonary disease, 
heart murmurs, and heart valve disease all had an increased odds of being a case.   
The use of any number of QT-prolonging medications in the 10 days prior to 
the event was predictive of ventricular arrhythmia or sudden death. Compared with 
patients who did not used any QT-prolonging medication, those who were exposed to 
1, 2, or more than 2 (≥3) QT drugs had 162%, 157%, and 211% higher odds of 
developing ventricular arrhythmia or sudden death (Table 2.4).  
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DISCUSSION 
In our study, we identified that concomitant exposure to one QT antibiotic and 
another QT-prolonging drug predicted ventricular arrhythmia and sudden death. 
Recent exposure to any QT-prolonging medication within 10 days was also predictive, 
and the strength of this relationship increased with increasing number of QT-
prolonging medications. To our knowledge, this is the first observational study to 
assess the association of ventricular arrhythmia or sudden death with concomitant use 
of QT-prolonging medications in a large, national, commercially insured population.   
There have been extensive pharmacokinetic and pharmacodynamic research on 
interactions between QT medications, and between QT-prolonging medications and 
other risk factors for ventricular arrhythmia.8,9,12,27,28 Case reports have also reported 
QT prolongation among patients exposed to multiple drugs with known risk of QT 
prolongation and TdP.29-31 Few studies have assessed the effects of receiving multiple 
QT-prolonging medications in retrospective studies. Several previous studies assessed 
the prevalence of concomitant use of antipsychotics that prolong QT interval.24,32 A 
study using claims from a pharmacy benefits manager in the United States found that 
51% of QT-prolonging antipsychotic users filled prescriptions for another QT 
medication with an overlap of at least 1 day in the durations of the two prescriptions.32 
Another study in a tertiary care hospital in Switzerland found that 38.7% (1,332/3,444) 
administered courses of macrolides or fluoroquinolones had concomitant use of 
additional QT-prolonging drugs.24  
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There have been general warnings regarding concomitant use of QT-
prolonging drugs and contraindications noted on many drug labels. These warnings 
may have contributed to the low prevalence of concomitant QT medication use in our 
cases and controls. During the study period, only 37 patients (0.2%) had concomitant 
use (QT antibiotic and other QT medication) within the 30-day window prior to 
ventricular arrhythmia or sudden death. Our sensitivity analysis also only identified 81 
patients (0.4%) with proximal use (QT antibiotic and other QT medication). Despite 
this infrequent use, concomitant (aOR 2.91) and proximal (aOR 2.20) use of QT 
medications was a strong predictor of ventricular arrhythmia and sudden death. These 
results suggest co-administration of medications with pro-arrhythmic potential should 
be avoided in clinical practice as the subsequent risk of ventricular arrhythmia and 
sudden death was high. 
Several risk factors for QT prolongation and outcomes of this have been 
identified in previous studies.7,8,12,17,22 Our study confirms several risk factors for QT 
prolongation, including hypokalemia, cardiac arrhythmia, cardiomyopathy, coronary 
artery disease, heart murmurs, heart valve disease, and palpitation. Our study provided 
the magnitude of these risk factors in a large national retrospective population. We 
also identified several new predictors in our population, such as myocardial infarction, 
diabetes without complications, metastatic solid tumor, congestive heart failure, 
chronic pulmonary disease, and mild liver disease. 
This study, however, is not without limitations. In lieu of actual drug 
administration information, we relied on dispensed prescriptions records from an 
administrative claims database as our measure of exposure. Therefore, inpatient 
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exposure to injected or intravenously administered QT-prolonging medications could 
not be assessed. In addition, several risk factors for ventricular arrhythmia and sudden 
death, such as smoking status and body mass index, were also not available from our 
data source. Other over-the-counter medications with QT-prolonging potential, such as 
diphenhydramine,33 are not captured by administrative data. Therefore, patients 
categorized as unexposed to QT-prolonging medications may have been misclassified. 
Finally, due to the nature of an administrative claims database, we relied on diagnosis 
codes for ventricular arrhythmia and sudden death. Therefore, had these events 
occurred but not resulted in claims with these specific diagnoses, misclassification of 
case-control status could have also occurred. We did utilize an outcome definition that 
has been validated in several populations.14,15  
Closer monitoring should be implemented when concomitant exposure of QT-
prolonging medications is necessary. Further research is still required for class specific 
combinations, dose-related effects, and interactions between medications and medical 
conditions. In our retrospective analysis, we only looked at antibiotics, 
antiarrhythmics, antihistamines, antidepressants, and antipsychotics while there are 
many other drugs with pro-arrhythmic potential (known, possible, and conditional 
according to CredibleMeds), which could be expanded in future studies.33 
Additionally, the interaction between QT medications and medical conditions is 
important area of future study as the physiologic and pathologic changes in patients 
might alter the metabolism and excretion of QT medications and disturb the balance of 
ions for normal ventricular myocyte function.34,35 
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CONCLUSION 
We confirmed several known predictors of QT prolongation in this privately-
insured adult population, including hypokalemia, cardiac arrhythmia, cardiomyopathy, 
coronary artery disease, heart murmurs, heart valve disease, palpitation, myocardial 
infarction, diabetes without chronic complication, metastatic solid tumor, congestive 
heart failure, chronic pulmonary disease, and mild liver disease. The concomitant 
exposure to a QT-prolonging antibiotic and other QT medication was predictive of 
ventricular arrhythmia or sudden death. Risk of ventricular arrhythmia or sudden death 
increased as the number of exposures to QT medications increased in the 10 days prior 
to the event. In clinical practice, exposure to multiple QT-prolonging medications 
should be avoided or closely monitored when necessary. 
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Table 2.1 Demographics and clinical characteristics of cases and controls 
Characteristics 
Cases 
(n=4,612) 
Controls 
(n= 18,448) 
 Mean SD Mean SD 
Age, y 59.5 13.7 59.5 13.7 
Charlson comorbidity index 2.8 3.1 0.5 1.3 
     
Charlson comorbidity index No. % No. % 
      0 1259 27.3 14537 78.8 
      1 876 19.0 1769 9.6 
      2 591 12.8 939 5.1 
      ≥3 1886 40.9 1203 6.5 
     
Comorbidities No. % No. % 
      AIDS/HIV 27 0.6 19 0.1 
      Angina pectoris 207 4.5 161 0.9 
      Any malignancy 745 16.2 782 4.2 
      Cardiac arrhythmia 1846 40.0 974 5.3 
      Cardiomyopathy 835 18.1 185 1.0 
      Cerebrovascular disease 647 14.0 571 3.1 
      Chronic kidney disease 849 18.4 449 2.4 
      Chronic pulmonary disease 1349 29.3 1244 6.7 
      Congestive heart failure 1456 31.6 464 2.5 
      Coronary artery disease 1450 31.4 1063 5.8 
      Dementia 64 1.4 90 0.5 
      Diabetes with chronic 
complication 
537 11.6 371 2.0 
      Diabetes without chronic 
complication 
1508 32.7 1554 8.4 
      Heart murmurs 133 2.9 118 0.6 
      Heart valve disease 1001 21.7 605 3.3 
      Hemiplegia or paraplegia 80 1.7 39 0.2 
      Hypokalemia 343 7.4 157 0.9 
      Metastatic solid tumor 240 5.2 81 0.4 
      Mild liver disease 361 7.8 267 1.4 
      Moderate or severe liver disease 47 1.0 22 0.1 
      Myocardial infarction 475 10.3 197 1.1 
      Palpitation 438 9.5 320 1.7 
      Peptic ulcer disease 85 1.8 70 0.4 
      Peripheral vascular disease 688 14.9 540 2.9 
      Renal disease 799 17.3 399 2.2 
      Rheumatic disease 181 3.9 205 1.1 
      Ventricular septal defect 0 0.0 1 0.0 
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Concomitant QT medication 
exposure 
No. % No. % 
Concomitant QT antibiotic and 
other    QT medication 30 days 
prior to index date 20 0.4 17 0.1 
Proximal QT antibiotic and other 
QT medication 30 days prior to 
index date 46 1.0 35 0.2 
Number of QT medication use 10 
days prior to index date 
    
      0 3310 71.8 17151 93.0 
      1 879 19.1 928 5.0 
      2 316 6.8 306 1.6 
      ≥3 107 2.3 66 0.4 
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Table 2.2 Concomitant QT drug use and predictors of ventricular arrhythmia or 
sudden death 
Study variable Adjusted odds 
ratio 
95% 
confidence 
interval 
Concomitant QT-prolonging medication use 
(QT antibiotic + other QT medication) 2.91 1.19-7.08 
Charlson comorbidity index   
      0 1.00 N/A 
      1 3.40 2.95-3.92 
      2 3.81 3.20-4.52 
      ≥3 4.67 3.82-5.72 
Comorbidities   
      Cardiac arrhythmia 3.58 3.11-4.11 
      Cardiomyopathy 2.01 1.54-2.62 
      Chronic pulmonary disease 1.40 1.22-1.60 
      Congestive heart failure 1.83 1.50-2.24 
      Coronary artery disease 1.86 1.61-2.15 
      Diabetes without chronic complication 1.26 1.10-1.44 
      Heart murmurs 1.48 1.03-2.12 
      Heart valve disease 1.48 1.26-1.74 
      Hypokalemia 2.11 1.62-2.74 
      Metastatic solid tumor 3.25 2.31-4.58 
      Mild liver disease 1.39 1.11-1.74 
      Myocardial infarction 1.36 1.08-1.76 
      Palpitation 1.74 1.40-2.15 
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Table 2.3 Proximal QT drug use (±15 days) and predictors of ventricular arrhythmia 
or sudden death 
Study variable Adjusted odds 
ratio 
95% 
confidence 
interval 
Proximal QT-prolonging medication use (QT 
antibiotic + other QT medication)* 2.2 1.23-3.40 
Charlson comorbidity index   
      0 1.00 N/A 
      1 3.40 2.95-3.92 
      2 3.50 3.20-4.52 
      ≥3 4.70 3.84-5.74 
Comorbidities   
      Cardiac arrhythmia 3.56 3.10-4.09 
      Cardiomyopathy 2.00 1.53-2.61 
      Chronic kidney disease 1.66 1.37-2.00 
      Chronic pulmonary disease 1.40 1.23-1.60 
      Congestive heart failure 1.83 1.50-2.24 
      Coronary Artery Disease 1.86 1.61-2.15 
      Diabetes without chronic complication 1.25 1.09-1.43 
      Heart murmurs 1.50 1.04-2.15 
      Heart valve disease (cortic stenosis) 1.47 1.25-1.73 
      Hypokalemia 2.11 1.63-2.75 
      Metastatic solid tumor 3.23 2.30-4.54 
      Mild liver disease 1.40 1.12-1.75 
      Myocardial infarction 1.39 1.09-1.78 
      Palpitation 1.74 1.41-2.16 
* ±15 days allowed between durations of prescriptions 
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Table 2.4 Number of QT-prolonging medications and predictors of ventricular 
arrhythmia or sudden death 
Study variable Adjusted odds 
ratio 
95% confidence 
interval 
Number of QT-prolonging drug used   
      0 1.00 N/A 
      1 2.62 2.28-3.01 
      2 2.57 2.05-3.22 
      ≥3 3.11 2.05-4.71 
Charlson comorbidity index   
      0 1.00 N/A 
      1 3.11 2.69-3.60 
      2 3.47 2.91-4.14 
      ≥3 4.11 3.35-5.06 
Comorbidities   
      Cardiac arrhythmia 3.58 3.11-4.11 
      Cardiomyopathy 2.01 1.54-2.62 
      Chronic pulmonary disease 1.40 1.22-1.60 
      Congestive heart failure 1.83 1.50-2.24 
      Coronary artery disease 1.86 1.61-2.15 
      Diabetes without chronic complication 1.26 1.10-1.44 
      Heart murmurs 1.48 1.03-2.12 
      Heart valve disease 1.48 1.26-1.74 
      Hypokalemia 2.11 1.62-2.74 
      Metastatic solid tumor 3.25 2.31-4.58 
      Mild liver disease 1.39 1.11-1.74 
      Myocardial infarction 1.36 1.08-1.76 
      Palpitation 1.74 1.40-2.15 
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ABSTRACT 
Background: Warnings regarding the increased risk of ventricular arrhythmia with 
azithromycin have been issued by regulatory agencies. However, conflicting results 
have been observed in retrospective studies evaluating this association.  
Objectives: To evaluate the 10-day and 30-day risk of ventricular arrhythmia or 
sudden death associated with azithromycin relative to amoxicillin in a national, 
commercially insured population.  
Methods: A retrospective cohort study was conducted using an administrative health 
claims database from a large national insurer. The study cohort consisted of patients 
who filled an outpatient prescription between 2011 and 2013 for macrolide and 
fluoroquinolone antibiotics, or amoxicillin. Amoxicillin episodes were 1-to-1 matched 
to macrolide and fluoroquinolone episodes on propensity scores. Inpatient admissions 
or emergency department visits with a primary diagnosis of ventricular arrhythmia 
were assessed within 10 days and 30 days of prescription dispensing using Cox 
proportional hazards models. 
Results: The use of azithromycin was not associated with an elevated 10-day (hazard 
ratio [HR]: 1.44, 95% confidence interval [CI]: 0.79-2.64, p=0.23) or 30-day (HR: 
1.17, 95% CI: 0.81-1.68, p=0.41) risk of ventricular arrhythmia or sudden death 
compared with amoxicillin. A class risk for macrolides or fluoroquinolones was also 
not observed. In a sensitivity analysis which expanded the outcome definition to 
include primary and secondary diagnoses, macrolides, as a class, had a 68% higher 10-
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day (HR: 1.68, 95% CI: 1.16-2.44, p=0.03) risk of ventricular arrhythmia or sudden 
death.  
Conclusions: Among a commercially insured population, azithromycin use was not 
associated with an increased risk of ventricular arrhythmia or sudden death compared 
with amoxicillin. Our findings suggest that the cardiac risk associated with 
azithromycin may be population specific.  
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BACKGROUND 
Macrolide and fluoroquinolone antibiotics are known to increase the risk of 
cardiac arrhythmia, including QT prolongation and torsades de pointes (TdP).1,2 
Several observational epidemiologic studies suggest that azithromycin may also have 
an increased risk of ventricular arrhythmia and sudden death.3-5 One retrospective 
cohort study published in 2012 reported a higher risk of cardiovascular death 
associated with azithromycin compared with no antibiotic use (hazard ratio [HR]: 
2.88, 95% confidence interval [CI]: 1.79-4.63) or amoxicillin (HR: 2.49, 95% CI: 
1.38-4.50) in a Medicaid population.4 One year later, the United States Food and Drug 
Administration (FDA) issued a warning to urge healthcare professionals to consider 
potential cardiovascular risks when prescribing azithromycin.6 Subsequent 
observational studies reported similar increased risks of serious arrhythmia, 
cardiovascular death, and all-cause mortality among patients taking azithromycin 
among Veterans Affairs patients and in the general population of Taiwan.3,5  
Meanwhile, several observational studies observed a relatively similar cardiac 
toxicity profile with azithromycin, as compared with no antibiotic use or other 
antibiotics.7-9 In the Danish adult population, azithromycin use (n = 1,102,050) was 
not associated with an increased risk of cardiovascular death compared to either no 
antibiotic use (rate ratio = 0.93, 95% CI 0.56-1.55) or penicillin-V use (adjusted 
absolute risk different = -1, 95% CI -9 to +11).8 Another study among the general 
population of Ontario, Canada found that macrolide antibiotic use was not associated 
with a higher risk of ventricular arrhythmia (relative risk [RR]: 1.06, 95% CI: 0.83–
1.36) compared to non-macrolide antibiotics.7 The same study also observed a lower 
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risk of all-cause mortality for azithromycin (RR: 0.82, 95% CI: 0.78–0.86) compared 
to non-macrolide antibiotics. 
Motivated by the FDA warnings and conflicting results observed in different 
populations worldwide, we sought to assess the risk of ventricular arrhythmia (VA) or 
sudden death (SD) for macrolide and fluoroquinolone antibiotics in database national 
commercially insured population in the United States (US) and compare the results 
with previously published observational studies.  
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METHODS 
Data source 
We utilized the de-identified Optum Clinformatics™ DataMart database 
(OptumInsight, Eden Prairie, MN) for this study, which is an administrative health 
claims database from a large national insurer. We utilized member eligibility files, 
medical claims, confinement claims, and pharmacy claims to conduct this study. 
Study population 
We identified outpatient prescription of oral macrolide antibiotics 
(azithromycin, clarithromycin, and erythromycin), fluoroquinolone antibiotics 
(ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, and ofloxacin), or 
amoxicillin (including amoxicillin-calvulanate) from January 1, 2011 to November 30, 
2013. The prescription fill date was defined as the index date (t0) of each antibiotic 
episode. Subsequent antibiotic episodes for each unique patient were only included 
when the subsequent index date was more than 30 days after the end date (index date 
+ days of supply) of a previous episode. Eligible antibiotic episodes were selected 
using the same criteria as previous studies.4 The inclusion criteria were (1) at least 1 
year of continuous enrollment prior to the index date for the assessment of baseline 
characteristics including medical history; and (2) at least 18 years of age on the index 
date. We excluded those that were (1) missing age or gender information; (2) 
hospitalized 30 days prior to the index date; (3) treated with multiple study antibiotics 
on the index date; (4) nursing home or other long-term care facility resident; and (5) 
previously diagnosed with cancer, organ transplant, congenital cardiovascular 
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anomalies, other congenital anomalies/childhood conditions, substance abuse, human 
immunodeficiency virus (HIV) infection, or life-threatening end-stage illness one year 
prior to the index date (Appendix B).4  
Drug exposure 
Eligible antibiotic episodes were categorized into three treatment groups and 
one control group based on filled outpatient oral antibiotics: (1) azithromycin; (2) all 
macrolide antibiotics, which included azithromycin, clarithromycin, and 
erythromycin; (3) all fluoroquinolones, which included ciprofloxacin, gemifloxacin, 
levofloxacin, moxifloxacin, and ofloxacin; and (4) amoxicillin serving as the active 
comparator group or control group for each of the three aforementioned treatment 
groups, which included amoxicillin alone and amoxicillin-clavulanate. Previous 
research has shown that amoxicillin use does not increase the risk of QT prolongation 
related cardiovascular outcomes.4,10 
Outcome definitions 
The study outcome was ventricular arrhythmia and sudden death (referred to as 
an “event” for the rest of the manuscript), defined as having a primary diagnosis 
during a hospitalization or first-listed emergency department (ED) visit for severe 
ventricular arrhythmia, cardiac arrest, sudden death, or instantaneous death 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-
9-CM] codes: 427.1, 427.4, 427.41, 427.42, 427.5, 798, 798.1, and 798.2). This 
outcome definition was validated in previous studies with positive predictive values 
(PPVs) of over 80%.11-14 Drug-induced QT prolongation is dose-related and the effect 
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diminishes quickly as study medications are metabolized and excreted.15 Therefore, 
we conducted the analysis on two study endpoints which were day 10 and day 30 after 
the index date.3,4,7  
Statistical Analysis 
Descriptive analyses were performed for the study cohort. The characteristics 
of the study population, including age, gender, year, month, and geographical region 
were assessed at the index date. Diagnoses of conditions related to indications were 
available in the data source and were controlled for in the propensity score. Medical 
history, medication use, and healthcare utilization were assessed from inpatient and 
outpatient diagnoses and procedures in the medical and confinement files, as well as 
from prescription information in the pharmacy files during the 1-year period before 
the index date (Appendix C).4  
In this study, propensity score matching was used to balance the baseline 
characteristics of the study groups for the purpose of estimating the probability of 
exposure.16 Propensity score methods allow one to minimize the effects of observed 
confounding when using observational data. For each comparison (azithromycin-
amoxicillin, macrolides-amoxicillin, fluoroquinolone-amoxicillin), a separate 
propensity score was calculated using logistic regression. The propensity score model 
was developed through an iterative, manual backward elimination approach using 
Wald statistics and likelihood ratio tests (p-value < 0.2 for main effects).17,18 Parson’s 
greedy matching was used to match within 0.000001 of the propensity score, without 
replacement, one amoxicillin episode from the control group to a single episode in 
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each of the three treatment groups. The adequacy of matching was assessed with a 
visual assessment of the distribution of propensity scores and by calculating the 
standardized difference between study groups.17 Differences of less than 10% were 
considered negligible between exposure groups.17 If important residual systematic 
differences were identified, interactions terms between covariates already in the model 
would be assessed.19 
In each matched comparison cohort, antibiotic episodes were followed for a 
minimum of 10 days and up to 30 days after the index date. Date of diagnosis of the 
outcome was used to define time to event. The Cox proportional hazards (PH) model 
was used to estimate the relative hazard of ventricular arrhythmia and sudden death by 
regressing survival on treatment status.16,20 The PH assumption was evaluated from 
the statistical significance of the correlation between the Schoenfeld residuals and the 
ranking of individual failure times.20 Since antibiotic episodes selected in matched 
cohorts were more likely to be similar to each other than randomly selected subjects, 
study outcomes were considered dependent within matched pairs. Therefore, the 
robust variance estimator was used to account for the matched nature of the study 
cohort. Estimated HR with 95% confidence intervals (CIs) for each comparison was 
obtained.   
For sensitivity analyses, we expanded the definition of the event from a 
primary diagnosis to any diagnoses within a hospitalization or ED visit. This 
definition has lower PPVs than the primary definition, however the PPVs for this 
definition are still over 70%.13 We also conducted a subgroup analysis among patients 
with a history of chronic kidney disease (CKD) because they have a higher risk of 
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developing QT prolongation. Studies have shown that patients with chronic kidney 
disease had longer QTc than patient without CKD.21,22 Furthermore, patients with 
CKD had impaired renal excretion of azithromycin, thereby leading to higher 
intravascular concentration of the drug. Because the pro-arrythmic effect of 
macrolides is dose-dependent, the increased concentration of the drug in patients with 
CKD may increase their risk of ventricular arrhythmia and sudden death.15,21,23 
All statistical analyses were performed using SAS Enterprise Guide, version 
7.1 (SAS Institute Inc., Cary, NC, USA). This study was reviewed and approved as 
exempt by the University of Rhode Island’s Institutional Review Board.  
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RESULTS 
Characteristic of the study cohorts 
The study population included 15,634,507 enrollees who filled a total of 
12,774,368 outpatient prescriptions for oral macrolide antibiotics (azithromycin, 
clarithromycin, and erythromycin), fluoroquinolone antibiotics (ciprofloxacin, 
gemifloxacin, levofloxacin, moxifloxacin, ofloxacin), and amoxicillin (including 
amoxicillin-calvulanate) during the study period. After applying the exclusion criteria, 
we identified 5,105,097 eligible prescriptions episodes: 28% azithromycin, 3% other 
macrolides (clarithromycin and erythromycin), 25% fluoroquinolones, and 43% 
amoxicillin (Table 3.1). The mean age of the entire study population was 45 years 
(range: 18-87) and 61% were female.   
Azithromycin, all macrolide and all fluoroquinolone episodes were matched 
1:1 to amoxicillin episodes on propensity scores. An equal number of amoxicillin 
prescription episodes were matched to azithromycin, all macrolides, and all 
fluoroquinolones. The azithromycin-amoxicillin cohort consisted of 1,329,575 
azithromycin prescription episodes with an equal number of amoxicillin prescriptions 
episodes. The fluoroquinolones-amoxicillin and macrolide-amoxicillin cohorts 
consisted of 1,096,138 and 1,457,873 prescription episodes of fluoroquinolone and 
macrolide prescription episodes, each with an equal number of amoxicillin 
prescriptions episodes (Figure 3.1). 
Propensity score matching resulted in similar propensity score distributions 
between the treatment and control groups (Appendix D).  The propensity score also 
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successfully balanced the study variables that contributed to the propensity score for 
each model, as measured by standardized differences (Appendix D).  Standardized 
differences suggested insignificant differences between the treatment and control 
groups. Therefore, interaction terms between covariates were not assessed. 
Ventricular arrhythmia or sudden death 
Azithromycin-amoxicillin 
We identified 1,329,575 azithromycin prescription episodes (mean age: 43 
years, females: 61%) and an equal number of propensity matched amoxicillin 
episodes. Among azithromycin recipients, there were 26 events (20 per 1 million 
episodes) during the 10-day follow-up period. During the same 10-day follow-up 
period, 18 events (13 per 1 million episodes) occurred among amoxicillin recipients. 
During the remaining 11-30 days of follow-up, 37 and 36 additional events occurred 
among azithromycin and amoxicillin recipients, respectively. The cumulative 
incidence was 47 and 41 per 1 million episodes for azithromycin and amoxicillin 
recipients, respectively. In time-to-event analyses, azithromycin was not associated 
with ventricular arrhythmia or sudden death, compared with amoxicillin (Figure 3.2). 
In the 10-day analysis, risk of ventricular arrhythmia or sudden death was elevated 
with azithromycin but not statistically significant (HR: 1.44, 95% CI: 0.79-2.64, 
p=0.230). In the longer follow-up period of 30 days, the risk remained non-significant 
for azithromycin with a lower HR of 1.17 (95% CI: 0.81-1.68, p=0.407). 
All macrolides-amoxicillin  
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We identified 1,457,873 macrolide prescription episodes (mean age: 43 years, 
females: 61%) and an equal number of propensity matched amoxicillin episodes. 
There were 26 and 23 events during the first 10 days after dispensing macrolides and 
amoxicillin, respectively, with an incidence of 18 and 16 per 1 million episodes, 
respectively.  During the 30-day follow-up period, 63 and 59 events occurred among 
all macrolides and amoxicillin recipients, respectively. Macrolide antibiotics were not 
associated with ventricular arrhythmia or sudden death in the 10-day (HR: 1.13, 95% 
CI: 0.64-1.98, p=0.669) and 30-day follow-up periods (HR: 1.07, 95% CI 0.75-1.52, 
p=0.717; Figure 3.3).   
All fluoroquinolones-amoxicillin 
We identified 1,096,138 fluoroquinolone prescription episodes (mean age: 46 
years, females: 63%) and an equal number of propensity matched amoxicillin episodes 
for this cohort. Among fluoroquinolone recipients, there were 24 events (22 per 1 
million episodes) during the 10-day follow-up period. During the same follow-up 
period, 22 events (20 per 1 million episodes) occurred among amoxicillin recipients. 
During the 30-day follow-up period, 64 and 59 events occurred among 
fluoroquinolone and amoxicillin recipients, respectively with a cumulative incidence 
of 58 and 54 per 1 million episodes for fluoroquinolone and amoxicillin recipients, 
respectively. Fluoroquinolones were not associated with ventricular arrhythmia or 
sudden death (Figure 3.4). In the 10-day follow-up period, the HR was 1.09 (95% CI: 
0.61-1.94, p=0.768), which decreased to 0.92 at 30-days (95% CI: 0.65-1.31, 
p=0.922).  
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Sensitivity Analysis 
Sensitivity analyses showed similar results when we expanded the event 
definition from a primary diagnosis only to any recorded diagnoses during hospital 
stays or ED visits. Azithromycin and fluoroquinolones were not associated with a 
higher risk of ventricular arrhythmia or sudden death compared with amoxicillin 
(Appendix E). The sensitivity analysis for macrolides also showed no increased risk in 
the 30-day follow-up period (HR: 1.24, 95% CI 0.97-1.58, p=0.950) but did 
demonstrate a significant increased risk of ventricular arrhythmia or sudden death at 
10 days (HR: 1.68, 95% CI 1.16-2.44, p=0.031, Figure 3.5).  
In the subgroup analysis among patients with chronic kidney disease, risk of 
ventricular arrhythmia or sudden death was similar in all comparison groups (10-day 
HR 1.65, 95% CI 0.39-6.90, p=0.493; 30-day HR 1.16, 95% CI 0.39-3.44, p=0.796; 
results not presented in tables or figures).  
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DISCUSSION 
In our study, we did not observe a significantly increased risk of ventricular 
arrhythmia or sudden death associated with azithromycin use alone, however when 
evaluating all macrolides, a 68% higher risk at 10 days was identified in our analysis 
of the event as either a primary or secondary diagnosis. To our knowledge, this is the 
first observational study to assess the association of ventricular arrhythmia and sudden 
death with azithromycin, all macrolides, and all fluoroquinolones in a large, national, 
commercially insured population. Our inclusion criteria were similar to those used in 
previous studies,3,4 and we evaluated the risk of cardiac adverse events at multiple 
time points (10 days and 30 days) so our results could be compared with these other 
studies.5,7 Furthermore, our study outcome has been validated in several 
populations.11,13,14 
It was previously thought that azithromycin did not exhibit a pro-arrhythmic 
potential as seen with the other macrolides, erythromycin and clarithromycin.24 Based 
on in vitro preclinical studies, azithromycin was observed to be weak cardiac human 
ether-a-go-go-related gene (hERG) potassium channel blocker, and it is widely 
recognized that pharmacological inhibition hERG potassium channel is correlated with 
drug-induced QT-prolongation.24-27 Azithromycin is also a group 3 cytochrome P-450 
CYP3A4 inhibitor which binds weakly with CYP3A4, and thus has less potential for 
adverse effects and drug-drug interactions with other CYP3A4 inhibitors such as 
erythromycin.10,28-30 However, we have observed a great discrepancy between in vitro 
studies and real-world clinical practice that is now largely recognized as the result of 
genetic factors.31 
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A previous population-based study in senior patients (age > 65 years) from 
Ontario, Canada reported no association between macrolide use and ventricular 
arrhythmia compared to non-macrolide antibiotic use in the 14 and 30 days after the 
index date.7 As compared with the Canadian study, we also assessed all macrolide 
antibiotics together and did not observe an increased risk at 30 days. However, our 
findings differed from the Canadian study at the shorter follow-up time point, where 
we observed a significant association with macrolides. Both studies assessed 
macrolides as the exposure of interest but different comparators were used. In our 
study, we selected amoxicillin as the comparator due to its low cardiovascular risk.4,10 
The comparator used in the Canadian study was defined as non-macrolide antibiotics, 
which included amoxicillin, cefuroxime, or levofloxacin. Levofloxacin is a 
fluoroquinolone antibiotic has been associated QT-prolonging effect.32,33 The 
inclusion of levofloxacin in the non-macrolide group may have diminished the risk 
difference between the study groups. Study outcomes were slightly different as well; 
we included both ventricular arrhythmia and sudden death, while the Canadian study 
only assessed ventricular arrhythmia. 
Our findings related to the risk of azithromycin and cardiac adverse events 
were in agreement with a population-based study from Denmark. In the Danish 
general population, there was no association between azithromycin use and the risk of 
cardiovascular death compared to either penicillin V (5-day rate ratio [RR] 0.93, 95% 
CI, 0.56-1.55) or no antibiotics (5-day RR 2.85, 95% CI, 1.13-7.24) in 5, 10, and 35 
day follow-up periods.8 Like our study population, the Danish general population was 
also younger (mean age for azithromycin use: 39.7 years) and healthier.8 Our study 
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varied from the Danish study, in that we used different comparators and a different 
definition of the study outcome.  
Alternatively, a study in the Tennessee Medicaid population observed a higher 
risk of cardiovascular death associated with azithromycin than with either no antibiotic 
use or amoxicillin use.4 Factors that may contribute to the conflicting study results 
between our study and the Tennessee Medicaid study include the different 
demographic and baseline characteristics of the study populations. Risk factors for 
drug-induced ventricular arrhythmia and sudden death include female gender,15,34 
older age,15,34 history of chronic kidney disease,21,35 hypokalemia,36,37 existing cardiac 
conditions,25 and use of other QT-prolonging medications.25,38 Unlike the Tennessee 
Medicaid study, our study was conducted in a younger, privately-insured population. 
Our propensity score matched cohorts were younger and healthier overall, with fewer 
comorbidities.4 In our study, the mean age of the azithromycin-amoxicillin matched 
cohort was 43 years, whereas that of the Tennessee Medicaid study was 48 years. In 
our azithromycin-amoxicillin cohort, only 2.0% had complications of diabetes, 0.9% 
had heart failure, 9.7% used angiotensin-converting-enzyme (ACE) inhibitors, 8.4% 
used beta-blockers, and 7.4% had inpatient stays. In the Tennessee Medicaid study, 
7.5% of their matched cohort had complications of diabetes, 4.3% had heart failure, 
28.1% used ACE inhibitors, 21.5% used beta-blockers, and 23.0% had inpatient stays. 
Our study also differed in the definition of the study outcome and prevalence of that 
outcome, as they assessed a broader definition of death, as cardiovascular rather than 
sudden death, and they did not assess rates of ventricular arrhythmia. In our study, the 
10-day cumulative incidence of ventricular arrhythmia and sudden death was 20 per 
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million azithromycin episodes. In contrast, the Tennessee Medicaid study reported the 
10-day cumulative incidence of cardiovascular death to be 360 per million 
azithromycin episodes. 
An increased risk of cardiac arrhythmias was also reported with azithromycin 
among Veterans in the US and in Taiwan. The VA study reported an increased 5-day 
risk of serious cardiac arrhythmias (HR 2.13, 95% CI 1.44-3.15) associated with 
azithromycin.3 Despite the same drug exposure group, there was a considerable age 
difference between the older VA population and ours (mean age 56 vs. 43 years). The 
VA study only assessed the outcome of ventricular arrhythmia, with a 10-day 
cumulative incidence rate of 200 per million azithromycin episodes. As mentioned 
above, the 10-day cumulative incidence of ventricular arrhythmia and sudden death 
was only 20 per million azithromycin episodes in our study. Similarly, azithromycin 
was associated with an increased 7-day risk of ventricular arrhythmia and sudden 
death (adjusted odds ratio [aOR] 4.32, 95% CI, 2.95–6.33) and cardiovascular death 
(aOR 2.62, 95% CI, 1.69–4.06) in the general population of Taiwan.5 Though our 
study population differed from the Taiwanese study population in many aspects, such 
as race/ethnicity and healthcare practice, azithromycin users were similar in several 
baseline characteristics, including age (45 vs. 43 years), and other comorbidities, 
including congestive heart failure (1.5% vs. 1.0%). Like our study, the Taiwanese 
study also used amoxicillin as the comparator. Nonetheless, the 7-day cumulative 
incidence rate was 520 per million azithromycin episodes in the Taiwanese general 
population since they used a broader definition of ventricular arrhythmia and sudden 
death from both inpatient and outpatient visits. This outcome definition which 
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included outpatient visits for ventricular arrhythmia and sudden death has not been 
validated and resulted in a high observed cumulative incidence in the general 
population of Taiwan. 
Several previous studies also observed diminishing risks during longer follow-
up periods. During the shorter follow-up period of 5 days, both the Tennessee 
Medicaid and VA studies reported an increased risk associated with azithromycin use 
as compared with amoxicillin use. During days 6 to 10 of follow-up, the risk was no 
longer significant in either the Tennessee Medicaid study (HR 0.88, 95% CI 0.43-
1.80) or the VA study (HR 0.73, 95% CI 0.49-1.10).3,4 For studies which assessed 30-
day risk, none reported an increased risk.7,8 
 Our study has several important limitations. In lieu of actual drug 
administration information, we relied on dispensed prescriptions records from an 
administrative claims database as our measure of exposure. Also, utilization of 
erythromycin and clarithromycin was uncommon in our population, therefore risk 
could not be assessed for individual macrolide antibiotics other than azithromycin. In 
addition, though diagnoses of infection were available in the data source and were 
controlled for in the propensity score, specific indications for each dispensed antibiotic 
were not available in the pharmacy claims data. In order to minimize the potential 
influence of confounding by the indication, we used amoxicillin, another antibiotic 
that has similar indications and minimal cardiac toxicity.4 Several risk factors for 
ventricular arrhythmia and sudden death, such as smoking status and body mass index 
were not available in our data source.15 Therefore, despite propensity score matching 
using predicted probabilities from a model which included many baseline covariates, 
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there was still potential for unmeasured confounding in our study.39 Another limitation 
was that our study could not assess a more proximal time frame to the prescription 
dispensing. Azithromycin is commonly prescribed for 5 days but we could only assess 
the study outcome at 10 days due to the low cumulative incidence observed in our 
study population. Finally, due to the nature of using an administrative claims database, 
we relied on diagnosis codes of ventricular arrhythmia and sudden death. Therefore, 
had these events occurred but not resulted in claims with these specific diagnoses, 
misclassification could have occurred.  It is difficult to measure the true prevalence of 
QT prolongation as there is no method to quantify undetected events.40,41 Without the 
true denominator, validated algorithms for QT prolongation identification report only 
PPV but not sensitivity/specificity for the same reason.11,42 We did attempt to use the 
most accurate definition possible, by using two methods with high PPVs for 
identifying the study outcome. Nevertheless, bias towards the null for all studies 
utilizing these definitions for identifying events related to QT prolongation is a 
possibility as we would not expect this misclassification to differ by exposure status.  
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CONCLUSION 
Among this privately-insured adult population, azithromycin and 
fluoroquinolones were not associated with a higher risk of ventricular arrhythmia and 
sudden death compared with amoxicillin. Macrolide antibiotics demonstrated a higher 
10-day risk of ventricular arrhythmia and sudden death compared with amoxicillin, 
suggesting a class effect, with differing quantitative risk between azithromycin and the 
other macrolides, clarithromycin and erythromycin.   
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Table 3.1 Demographics and clinical characteristics of the study population 
Characteristics AMO AZI MAC FLQ 
Prescriptions (no.) 2,220,068 1,454,889 1,608,020 1,277,009 
Prescriptions / patient (no.) 1.7 1.7 1.8 1.8 
Mean age ± SD (year) 43.7±14.2 43.5±14.0 43.6±13.5 47.2±14.1 
Female (%) 59.2 61.8 61.7 64.6 
Year (%)     
      2011 32.6 31.5 31.9 33.5 
      2012 34.8 34.9 34.7 35.0 
      2013 32.6 33.6 33.4 31.5 
Month (%)     
      January 10.7 10.9 10.9 10.5 
      February 9.7 10.0 10.0 9.5 
      March 9.5 9.6 9.6 9.3 
      April 8.1 8.1 8.1 8.0 
      May 7.9 7.8 7.8 7.9 
      June 7.1 6.7 6.7 7.2 
      July 6.7 6.2 6.2 6.8 
      August 7.1 6.7 6.7 7.3 
      September 7.4 7.4 7.4 7.6 
      October 8.4 8.3 8.3 8.5 
      November 8.8 9.1 9.1 8.8 
      December 8.8 9.3 9.2 8.7 
Region (%)     
      Northeastern 10.3 13.1 12.9 10.2 
      Midwest 26.7 22.8 22.6 22.6 
      South 47.7 52.6 52.7 53.5 
      West 15.3 11.5 11.7 13.7 
Comorbidities (%)     
      Angina 0.6 0.7 0.7 0.9 
      Acute myocardial infarction 0.6 0.5 0.5 0.8 
      Other coronary heart disease 3.4 3.3 3.3 4.8 
      Heart valve disease 2.9 2.6 2.6 3.5 
      Conduction disorder 0.9 0.8 0.8 1.2 
      Atrial fibrillation 1.2 1.0 1.0 1.5 
      Cardiac arrhythmia 4.1 4.0 4.0 5.5 
      Congestive heart failure 1.1 1.0 1.0 1.7 
      Hypertension 23.1 23.7 23.8 30.1 
      Other cardiovascular disease 4.2 3.9 3.9 5.4 
      Hyperlipidemia 24.9 25.7 25.8 31.7 
      Hyperkalemia 0.2 0.2 0.2 0.4 
      Chronic kidney disease 1.2 1.1 1.1 2.0 
      Rheumatic disease 31.6 32.5 32.7 37.4 
      Chronic liver disease 2.4 2.5 2.5 3.7 
      Chronic lung disease 8.8 11.2 11.5 13.0 
Medication use history (%)     
      Angiotensin-converting-enzyme 
inhibitor 
10.4 10.1 10.2 12.9 
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      Angiotensin receptor blocker 5.9 6.2 6.2 8.2 
      Aspirin 0.4 0.4 0.4 0.5 
      Sodium-channel blocker 0.2 0.1 0.1 0.2 
      Beta-blocker 9.1 8.9 8.9 11.7 
      Potassium-channel blocker 0.3 0.2 0.2 0.4 
      Calcium-channel blocker 6.0 6.0 6.0 8.0 
      Digoxin 0.3 0.2 0.2 0.3 
      Loop diuretic 1.9 1.9 1.9 3.2 
      Other diuretic 11.2 11.5 11.5 14.5 
      Insulin 1.9 1.8 1.8 2.7 
      Oral anti-diabetic 6.2 6.2 6.2 8.2 
      Beta-agonist 9.4 12.7 13.0 13.2 
      Statins 15.4 15.1 15.1 20.0 
      Fibrate lipid-lowering agent 1.9 1.9 1.9 2.6 
      Nitrate antianginal 0.8 0.8 0.8 1.2 
      Other antihypertensive 2.2 2.0 2.0 4.0 
      Peripheral vasodilator 0.2 0.2 0.2 0.3 
      Platelet inhibitor, none aspirin 1.1 1.1 1.1 1.6 
      Tricyclic/tetracyclic antidepressant 2.3 2.3 2.3 3.2 
      SSRI/SNRI antidepressant 11.5 12.1 12.2 14.2 
      Trazodone antidepressant 1.8 1.8 1.8 2.4 
      Other antidepressant 3.1 3.1 3.1 3.8 
      Lithium 0.2 0.2 0.2 0.2 
      Atypical antipsychotic 1.2 1.1 1.1 1.5 
      Other antipsychotic 0.3 0.4 0.4 0.5 
      Benzodiazepine anticonvulsant 6.4 7.0 7.0 8.4 
      GABA agonist anticonvulsant 3.1 3.1 3.1 4.6 
      Hydroxyzine 0.8 1.0 1.0 1.1 
      Other bronchodilator 1.0 1.4 1.4 2.0 
Healthcare utilization (%)     
      Any none study drug prescription 
past 30 days 
60.7 62.6 62.9 69.5 
      Any antibiotic use past 30 days 7.6 7.2 7.4 9.2 
      Any outpatient visit past 30 days 42.0 42.7 42.9 48.0 
      Any outpatient visits 30-365 days 86.6 88.7 88.9 91.2 
      Any ED visit past 7 days 1.0 1.0 1.0 1.1 
      Any hospitalization past 30 days 0.4 0.3 0.3 0.5 
      Any hospitalization past 30-365 
days 
7.9 7.4 7.4 10.6 
AMO = Amoxicillin, AZI = Azithromycin, ED = Emergency Department, FLQ = 
Fluoroquinolone Antibiotics, GABA = Gamma-Amino Butyric Acid, oMAC = Other 
Macrolide Antibiotics; SD = Standard Deviation, SNRI = Serotonin–Norepinephrine 
Reuptake Inhibitor, SSRI = Selective Serotonin Reuptake Inhibitors 
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Figure 3.1 Study cohort selection process 
 
  
  
12,774,368 episodes of outpatient oral macrolide antibiotics, fluoroquinolone antibiotics, and 
amoxicillin identified from January 2011 to December 2013 
7,669,271 episodes excluded 
1,831,459: filled less than 30-days from previous episode 
3,100,467: less than 1 year of continuous enrollment 
          400: missing sex or age 
2,061,983: patient < 18 years on index date 
   674,255: having exclusion conditions 
    707: multiple study drugs filled on the same day 
5,105,097 episodes of eligible antibiotic episodes 
1,608,020: all macrolides 
1,454,889: azithromycin 
         153,131: clarithromycin and erythromycin 
2,220,068: amoxicillin  
1,277,009: all fluoroquinolones 
 
1:1 matched on propensity score 
Azithromycin (1,329,575) 
vs. amoxicillin (1,329,575) 
All macrolides (1,457,873) 
vs. amoxicillin (1,457,873) 
All fluoroquinolones 
(1,096,138) vs. amoxicillin 
(1,096,138) 
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Figure 3.2 Cumulative incidence of ventricular arrhythmia and sudden death with 
azithromycin and amoxicillin 
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Figure 3.3 Cumulative incidence of ventricular arrhythmia and sudden death with 
macrolides and amoxicillin 
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Figure 3.4 Cumulative incidence of ventricular arrhythmia and sudden death with 
fluoroquinolones and amoxicillin 
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Figure 3.5 Cumulative incidences of ventricular arrhythmia and sudden death with 
fluoroquinolones and amoxicillin in all diagnoses 
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APPENDICES 
Appendix A. List of medications and comorbidities associated with QT prolongation 
Medications and comorbidities associated with QT prolongation 
Macrolide antibiotics 
      Azithromycin 
      Clarithromycin 
      Erythromycin 
Fluoroquinolone antibiotics 
      Ciprofloxacin 
      Gemifloxacin 
      Levofloxacin 
      Moxifloxacin 
      Ofloxacin 
Antidepressants 
      Amitriptyline 
      Citalopram 
      Clomipramine 
      Desipramine 
      Doxepin 
      Escitalopram 
      Fluoxetine 
      Imipramine 
      Mirtazapine 
      Nortriptyline 
      Paroxetine 
      Sertraline 
      Trazodone 
      Trimipramine 
      Venlafaxine 
Antipsychotics 
      Aripiprazole 
      Asenapine 
      Chlorpromazine 
      Clozapine 
      Droperidol 
      Haloperidol 
      Iloperidone 
      Lithium 
      Olanzapine 
      Paliperidone 
      Perphenazine 
      Pimozide 
      Promethazine 
      Quetiapine 
      Risperidone 
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      Thioridazine 
      Ziprasidone 
Antihistamines 
      Diphenhydramine 
      Hydroxyzine 
Antiarrhythmics 
      Amiodarone 
      Disopyramide 
      Dofetilide 
      Dronedarone 
      Flecainide 
      Ibutilide 
      Procainamide 
      Quinidine 
      Sotalol 
Comorbidities 
      Angina pectoris  
      Cardiac arrhythmia 
      Cardiomyopathy 
      Coronary artery disease (CAD) 
      Heart murmur 
      Heart valve disease (including aortic stenosis), 
      Palpitation 
      Ventricular septal defect (VSD) 
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Appendix B. Exclusion criteria for manuscript III 
Disease Definition and ICD-9-CM diagnostic codes 
Cancer  Diagnosis of cancer (except for non-melanomous skin 
cancers) or selected antineoplastic agents. Includes 
neoplasms uncertain behavior, ICD9-CM codes 235-
238, except: 238.2 (skin), 238.9 (site unspecified), 
237.70, 237.71 (neurofibromatosis), 238.4 
(polycythemia v.), 238.7 (lymphoproliferative disease), 
285.22 (anemia in neoplastic disease) 
 
AIDS   Diagnosis of AIDS or use of antiretroviral agents or 
pentamadine 
 
Severe Hepatic disease Diagnoses 570-573 
 
 
Organ transplant Includes kidney, heart, lung, liver, bone marrow, and 
pancreas. Includes 996.8 
 
 
Serious neuromuscular Multiple sclerosis (340), ALS (335.20), Duchenne's 
muscular dystrophy (335.21), Huntington's chorea 
(333.4), quadriplegia, paraplegia, or spinal cord injury. 
Recent stroke (inpatient with primary discharge 
diagnosis of 430, 431, 433.x1, 434, 436) with 
hemiplegia/hemiparesis (342,438.2) 
 
Cardiovascular congenital 
anomalies  
Common truncus (745.0) transposition great vessels 
(745.1), tetrology (745.2), common ventricle (745.3), 
endocardial cushion defect (745.6), pulmonary atresia 
(746.0), tricuspid atresia (746.1), hypoplastic left heart 
(746.7), coarctation of aorta (747.1), other anomalies of 
aorta (747.2), total anomalous pulmonary venous 
connection (747.41) . A single diagnosis is sufficient for 
exclusion 
 
Other congenital 
anomalies/childhood 
conditions 
 
Sickle cell (282.6), cerebral palsy (343), spina bifida 
(741), Down's syndrome (758.0), hydrocephalus 
(742.3), microcephalus (742.1), encephalocele (742.0), 
severe mental retardation (318.1, 318.2), cystic fibrosis 
 
Other end-stage illness 
 
a. Hospice care. b. Diagnosis of coma, vegetative state, 
debility (799.3). c. Total parenteral nutrition, PEG, 
enteral feeding, malnutrition (260, 261,262, 263) when 
these are for outpatients. d. Gangrene (040, gas 
gangrene; 785.4 gangrene: single diagnosis sufficient) e. 
Intravenous medications outside of the hospital, as 
indicated by procedures for IV access outside a hospital 
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stay period 
 
Drug abuse Includes all medications and drugs with abuse potential 
and with the exception of alcohol (unless hospitalization 
with primary discharge diagnosis: 291.x, 303.x, 305.0, 
980.0, 980.9, E860.0, E860.1, E860.9) and tobacco. 
Codes are 292.0 (drug withdrawal syndrome), 304.x 
(drug dependence), 305.2-305.9 (drug abuse, except 
alcohol/tobacco, 305.9 is abuse NOS, may be 
nonspecific, but better to exclude), 965.01 (accidental 
poisoning, heroin), 969.6 (poisoning, psychodysleptic 
[hallucinogens]), 970.81 (cocaine poisoning, added in 
2010), E8500 (heroin poisoning), E8541 
(psychodysleptic poisoning) 
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Appendix C. List of covariates for propensity score model 
Covariates for propensity score model 
Number of prescriptions for an unique patient 
Age 
Gender 
Year 
Month 
Geographic region 
Angina/angina pectoris 
Acute myocardial infarction 
Other coronary heart disease 
Other cardiovascular disease 
Heart valve disease 
Conduction disorder 
Atrial fibrillation 
Cardiac arrhythmia 
Congestive heart failure 
Hemorrhagic stroke 
Ischemic stroke 
Transient ischemic attack 
Obesity, diagnosed, not morbid 
Morbid obesity, diagnosed 
Hypertension 
Malignant hypertension 
Hyperlipidemia 
Peripheral vascular disease 
Diabetes mellitus 
Diabetes, ocular complication 
Diabetes, neurologic complication 
Diabetes, skin complication 
Diabetes, renal complication 
Diabetes, other complication 
Schizophrenia or other psychotic disorders 
Alcohol abuse 
Bipolar disorder 
Unipolar depression and/or anxiety disorder 
Parkinson's Disease 
Seizure disorder 
Dementia 
Other cognitive disorders 
Chronic lung disease 
COPD and other respiratory conditions 
Asthma 
Diagnosed smoking 
Rheumatic disease 
Chronic liver disease 
Chronic kidney disease 
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Acute kidney disease 
Hypokalemia 
Fluid and electrolyte disorders 
Cardiac revascularization 
ACE inhibitor 
Anticoagulant 
Angiotensin receptor blocker 
Aspirin 
Na+-channel blocker 
Beta-adrenergic blocker 
K+-channel blocker 
Ca2+-channel blocker 
Digoxin 
Loop diuretic 
Other diuretic 
Insulin 
Oral antidiabetic 
Statin 
Fibrate lipid-lowering agent 
Nitrate anti-anginal 
Other antihypertensive 
Peripheral vasodilator 
Platelet inhibitor, not aspirin 
Tricyclic/tetracyclic antidepressant 
SSRI/SNRI antidepressant 
Trazodone antidepressant 
Other antidepressant 
Lithium antipsychotic 
Atypical antipsychotics 
Other antipsychotics 
Benzodiazepine anticonvulsants 
GABA agonist anticonvulsant 
Hydroxyzine 
Adrenergic beta-agonist 
Other bronchodilator 
Any prescription (other than study antibiotics) past 30 days 
Any antibiotic use past 30 days 
Any outpatient visit past 30 days 
Any outpatient visits 30-365 days 
Any ED visit past 7 days 
Any hospitalization past 30 days 
Any hospitalization past 30-365 days 
ACE = angiotensin converting enzyme, COPD = chronic obstructive pulmonary 
disease, ED = emergency department, GABA = gamma-amino butyric acid 
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Appendix D. Distributions of propensity scores in matched study cohorts 
 
Matched AMO-AZI cohort (0: AMO; 1: AZI) 
  
Matched AMO-MAC cohort (0: AMO; 1: MAC) 
 
Matched AMO-FLQ cohort (0: AMO; 1: FLQ) 
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Appendix E. Demographics and clinical characteristics of the matched cohorts 
Appendix Table E.1 Demographics and clinical characteristics of the matched AZI-
AMO cohort 
Characteristics AMO AZI d 
Prescriptions (no.) 1,329,575 1,329,575 0.000 
Mean prescriptions / patient (no.)* 1.68 1.67 0.002 
Mean age* 43.0 43.1 0.009 
Female (%)* 61.0 61.1 0.007 
Year (%)*    
      2011 32.3 32.1 0.005 
      2012 34.9 34.9 0.001 
      2013 32.8 33.0 0.004 
Month (%)*    
      January 10.8 11.0 0.006 
      February 9.7 10.1 0.011 
      march 9.5 9.6 0.004 
      April 8.1 8.1 0.001 
      May 8.0 7.8 0.006 
      June 7.0 6.7 0.011 
      July 6.6 6.2 0.016 
      August 7.0 6.7 0.012 
      September 7.4 7.3 0.001 
      October 8.3 8.3 0.000 
      November 8.9 9.0 0.004 
      December 8.8 9.2 0.015 
Region (%)*    
      Northeastern 11.1 12.1 0.034 
      Midwest 26.3 22.7 0.084 
      South 49.1 53.5 0.088 
      West 13.5 11.7 0.056 
Comorbidities (%)    
      Angina/angina pectoris* 0.6 0.6 0.000 
      Acute myocardial infarction 0.5 0.5 0.002 
      Other coronary heart disease 3.0 3.0 0.001 
      Other cardiovascular disease* 3.5 3.5 0.002 
      Heart valve disease* 2.3 2.4 0.002 
      Conduction disorder* 0.7 0.7 0.000 
      Atrial fibrillation 0.8 0.7 0.004 
      Cardiac arrhythmia* 3.5 3.5 0.000 
      Congestive heart failure 0.9 0.9 0.001 
      Hemorrhagic stroke 0.0 0.0 0.001 
      Ischemic stroke 0.3 0.3 0.002 
      Transient ischemic attack 0.3 0.3 0.002 
      Obesity, diagnosed, not morbid 5.0 5.0 0.000 
      Morbid obesity, diagnosed* 1.6 1.6 0.002 
      Hypertension* 22.0 22.5 0.011 
      Malignant hypertension* 0.8 0.8 0.002 
      Hyperlipidemia* 24.4 24.5 0.003 
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      Peripheral vascular disease* 1.3 1.3 0.001 
      Diabetes mellitus 10.9 11.0 0.003 
      Diabetes, ocular complication 0.5 0.5 0.001 
      Diabetes, neurologic complication* 0.6 0.6 0.001 
      Diabetes, skin complication* 0.2 0.2 0.000 
      Diabetes, renal complication 0.3 0.3 0.000 
      Diabetes, other complication 0.5 0.5 0.001 
      Schizophrenia or other psychotic disorders 0.2 0.2 0.002 
      Alcohol abuse* 0.4 0.4 0.000 
      Bipolar disorder* 0.9 0.9 0.001 
      Unipolar depression and/or anxiety disorder 14.6 14.7 0.002 
      Parkinson's Disease* 0.1 0.1 0.001 
      Seizure disorder 0.7 0.7 0.003 
      Dementia 0.1 0.1 0.000 
      Other cognitive disorders 0.2 0.2 0.001 
      Chronic lung disease* 8.5 8.6 0.003 
      COPD and other respiratory conditions* 1.7 1.7 0.001 
      Asthma* 6.3 6.4 0.003 
      Diagnosed smoking* 3.8 3.9 0.006 
      Rheumatic disease 31.3 31.5 0.004 
      Chronic liver disease 2.4 2.4 0.002 
      Chronic kidney disease* 1.2 1.3 0.001 
      Hypokalemia 0.2 0.2 0.000 
      Fluid and electrolyte disorders 0.2 0.2 0.000 
      Cardiac revascularization 0.0 0.0 0.000 
Medication use history (%)    
      ACE inhibitor* 9.6 9.7 0.006 
      Anticoagulant* 0.8 0.8 0.001 
      Angiotensin receptor blocker* 5.7 5.8 0.003 
      Aspirin 0.4 0.4 0.001 
      Na+-channel blocker* 0.1 0.1 0.002 
      Beta-adrenergic blocker* 8.3 8.4 0.004 
      K+-channel blocker* 0.1 0.1 0.004 
      Ca2+-channel blocker 5.6 5.6 0.001 
      Digoxin* 0.1 0.1 0.002 
      Loop diuretic 1.7 1.7 0.002 
      Other diuretic* 10.8 10.9 0.004 
      Insulin* 1.7 1.7 0.000 
      Oral antidiabetic* 5.8 5.9 0.004 
      Statin* 14.4 14.5 0.003 
      Fibrate lipid-lowering agent 1.8 1.8 0.000 
      Nitrate anti-anginal* 0.7 0.7 0.001 
      Other antihypertensive* 1.9 1.9 0.000 
      Peripheral vasodilator 0.2 0.2 0.001 
      Platelet inhibitor, not aspirin 1.0 1.0 0.002 
      Tricyclic/tetracyclic antidepressant 2.2 2.2 0.006 
      SSRI/SNRI antidepressant 11.6 11.7 0.004 
      Trazodone antidepressant 1.8 1.7 0.005 
      Other antidepressant* 3.0 3.0 0.000 
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      Lithium antipsychotic* 0.2 0.2 0.001 
      Atypical antipsychotics* 1.1 1.1 0.002 
      Other antipsychotics 0.3 0.3 0.001 
      Benzodiazepine anticonvulsants* 6.4 6.4 0.001 
      GABA agonist anticonvulsant 2.9 2.9 0.002 
      Hydroxyzine* 0.9 0.9 0.000 
      Adrenergic beta-agonist* 9.4 9.4 0.003 
      Other bronchodilator* 0.9 0.9 0.000 
Healthcare Utilization (%)    
      Any prescription (other than study ABX) past 30 
days* 
60.2 60.8 0.013 
      Any antibiotic use past 30 days* 6.9 7.1 0.007 
      Any outpatient visit past 30 days 41.5 41.7 0.003 
      Any outpatient visits 30-365 days* 88.4 88.0 0.010 
      Any ED visit past 7 days 1.0 1.0 0.000 
      Any hospitalization past 30 days* 0.3 0.3 0.000 
      Any hospitalization past 30-365 days* 7.1 7.0 0.003 
* Covariates included the propensity score model 
C-statistic: 0.547 
Hosmer and Lemeshow Goodness-of-Fit (GOF) test: χ2=121.7 (degree of freedom [df] = 8, p-
value < 0.0001) 
ABX = antibiotics, ACE = angiotensin converting enzyme, AMO = amoxicillin, AZI = 
azithromycin, COPD = chronic obstructive pulmonary disease, ED = emergency department, 
GABA = gamma-amino butyric acid 
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Appendix Table E.2 Demographics and clinical characteristics of the matched MAC-
AMO cohort 
Characteristics AMO MAC d 
Prescriptions (no.) 1,457,873 1,457,873 0.000 
Mean prescriptions / patient (no.)* 1.7 1.7 0.037 
Mean age* 43.0 43.0 0.004 
Female (%)* 61.6 61.4 0.005 
Year (%)    
      2011 31.5 32.0 0.013 
      2012 34.9 34.8 0.002 
      2013 33.6 33.2 0.010 
Month (%)*    
      January 10.8 10.9 0.005 
      February 9.9 10.0 0.005 
      march 9.6 9.6 0.001 
      April 8.1 8.1 0.000 
      May 7.9 7.8 0.001 
      June 6.9 6.8 0.006 
      July 6.4 6.3 0.008 
      August 6.9 6.7 0.006 
      September 7.4 7.4 0.002 
      October 8.3 8.3 0.000 
      November 9.0 9.0 0.003 
      December 9.0 9.2 0.005 
Region (%)*    
      Northeastern 11.6 12.2 0.021 
      Midwest 24.2 22.7 0.044 
      South 51.3 53.3 0.058 
      West 12.9 11.9 0.038 
Comorbidities (%)    
      Angina/angina pectoris* 0.5 0.5 0.001 
      Acute myocardial infarction* 0.4 0.4 0.002 
      Other coronary heart disease* 2.7 2.7 0.001 
      Other cardiovascular disease* 3.1 3.2 0.001 
      Heart valve disease* 2.1 2.1 0.002 
      Conduction disorder* 0.6 0.6 0.001 
      Atrial fibrillation* 0.7 0.6 0.002 
      Cardiac arrhythmia* 3.2 3.2 0.002 
      Congestive heart failure 0.8 0.8 0.002 
      Hemorrhagic stroke 0.0 0.0 0.000 
      Ischemic stroke* 0.3 0.3 0.000 
      Transient ischemic attack 0.3 0.3 0.003 
      Obesity, diagnosed, not morbid 4.8 4.8 0.001 
      Morbid obesity, diagnosed* 1.6 1.5 0.001 
      Hypertension* 21.1 21.2 0.003 
      Malignant hypertension* 0.7 0.7 0.002 
      Hyperlipidemia* 23.6 23.5 0.001 
      Peripheral vascular disease* 1.2 1.2 0.000 
      Diabetes mellitus* 10.3 10.3 0.001 
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      Diabetes, ocular complication* 0.4 0.4 0.000 
      Diabetes, neurologic complication 0.5 0.5 0.003 
      Diabetes, skin complication* 0.2 0.2 0.002 
      Diabetes, renal complication* 0.2 0.2 0.001 
      Diabetes, other complication 0.5 0.5 0.001 
      Schizophrenia or other psychotic disorders 0.2 0.2 0.001 
      Alcohol abuse* 0.4 0.4 0.002 
      Bipolar disorder 0.8 0.8 0.002 
      Unipolar depression and/or anxiety disorder 14.3 14.5 0.004 
      Parkinson's Disease 0.1 0.1 0.000 
      Seizure disorder 0.7 0.7 0.004 
      Dementia* 0.0 0.0 0.000 
      Other cognitive disorders 0.1 0.1 0.001 
      Chronic lung disease* 8.5 8.5 0.002 
      COPD and other respiratory conditions* 1.5 1.5 0.002 
      Asthma* 6.5 6.6 0.002 
      Diagnosed smoking* 3.5 3.6 0.007 
      Rheumatic disease* 30.7 31.1 0.007 
      Chronic liver disease* 2.2 2.2 0.003 
      Chronic kidney disease* 1.0 1.0 0.002 
      Hypokalemia 0.2 0.2 0.001 
      Fluid and electrolyte disorders 0.2 0.2 0.001 
      Cardiac revascularization* 0.0 0.0 0.001 
Medication use history (%)    
      ACE inhibitor* 9.1 9.2 0.003 
      Anticoagulant* 0.7 0.7 0.001 
      Angiotensin receptor blocker* 5.3 5.4 0.003 
      Aspirin 0.4 0.4 0.001 
      Na+-channel blocker* 0.1 0.1 0.003 
      Beta-adrenergic blocker* 7.7 7.8 0.002 
      K+-channel blocker* 0.1 0.1 0.002 
      Ca2+-channel blocker* 5.3 5.3 0.003 
      Digoxin 0.1 0.1 0.001 
      Loop diuretic* 1.6 1.6 0.002 
      Other diuretic* 10.2 10.3 0.004 
      Insulin* 1.5 1.6 0.002 
      Oral antidiabetic 5.6 5.6 0.001 
      Statin* 13.8 13.7 0.002 
      Fibrate lipid-lowering agent* 1.7 1.7 0.000 
      Nitrate anti-anginal 0.6 0.6 0.003 
      Other antihypertensive* 1.8 1.8 0.002 
      Peripheral vasodilator* 0.1 0.1 0.000 
      Platelet inhibitor, not aspirin* 0.9 0.9 0.001 
      Tricyclic/tetracyclic antidepressant* 2.0 2.0 0.005 
      SSRI/SNRI antidepressant* 11.4 11.5 0.003 
      Trazodone antidepressant* 1.7 1.7 0.005 
      Other antidepressant* 2.8 2.8 0.002 
      Lithium antipsychotic* 0.1 0.2 0.002 
      Atypical antipsychotics* 1.0 1.0 0.001 
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      Other antipsychotics* 0.3 0.3 0.001 
      Benzodiazepine anticonvulsants* 6.0 6.1 0.004 
      GABA agonist anticonvulsant* 2.6 2.7 0.003 
      Hydroxyzine* 0.8 0.8 0.002 
      Adrenergic beta-agonist* 9.6 9.6 0.000 
      Other bronchodilator* 0.8 0.8 0.001 
Healthcare Utilization (%)    
      Any prescription (other than study ABX) past 30 
days* 
60.8 60.6 0.004 
      Any antibiotic use past 30 days* 7.3 7.1 0.006 
      Any outpatient visit past 30 days* 41.5 41.4 0.001 
      Any outpatient visits 30-365 days* 88.1 88.0 0.001 
      Any ED visit past 7 days 1.0 1.0 0.003 
      Any hospitalization past 30 days 0.3 0.3 0.001 
      Any hospitalization past 30-365 days* 6.6 6.6 0.003 
* Covariates included the propensity score model 
C-statistic: 0.546 
Hosmer and Lemeshow Goodness-of-Fit (GOF) test: χ2=153.7 (df = 8, p-value < 0.0001) 
ABX = antibiotics, ACE = angiotensin converting enzyme, AMO = amoxicillin, COPD = 
chronic obstructive pulmonary disease, ED = emergency department, GABA = gamma-amino 
butyric acid, MAC = macrolide antibiotics 
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Appendix Table E.3 Demographics and clinical characteristics of the matched FLQ-
AMO cohort 
Characteristics AMO FLQ d 
Prescriptions (no.) 1,096,138 1,096,138 0.000 
Mean prescriptions / patient (no.)* 1.7 1.7 0.005 
Mean age* 45.6 45.7 0.007 
Female (%)* 63.8 64.1 0.006 
Year (%)    
      2011 33.9 33.5 0.008 
      2012 35.0 34.9 0.001 
      2013 31.1 31.5 0.009 
Month (%)*    
      January 10.8 10.7 0.003 
      February 9.8 9.6 0.007 
      march 9.5 9.4 0.003 
      April 8.1 8.1 0.003 
      May 7.8 7.9 0.003 
      June 7.0 7.1 0.005 
      July 6.7 6.8 0.002 
      August 7.1 7.2 0.003 
      September 7.4 7.6 0.004 
      October 8.4 8.4 0.000 
      November 8.7 8.8 0.001 
      December 8.7 8.7 0.000 
Region (%)*    
      Northeastern 9.7 10.4 0.025 
      Midwest 25.5 22.7 0.065 
      South 49.3 53.4 0.081 
      West 15.5 13.5 0.057 
Comorbidities (%)    
      Angina/angina pectoris* 0.7 0.7 0.001 
      Acute myocardial infarction* 0.6 0.6 0.000 
      Other coronary heart disease* 3.8 3.8 0.000 
      Other cardiovascular disease* 4.5 4.5 0.002 
      Heart valve disease* 3.2 3.1 0.004 
      Conduction disorder* 1.0 0.9 0.001 
      Atrial fibrillation* 1.3 1.3 0.003 
      Cardiac arrhythmia* 4.5 4.5 0.003 
      Congestive heart failure 1.2 1.2 0.001 
      Hemorrhagic stroke 0.0 0.0 0.001 
      Ischemic stroke* 0.4 0.4 0.001 
      Transient ischemic attack 0.4 0.4 0.000 
      Obesity, diagnosed, not morbid 5.5 5.5 0.001 
      Morbid obesity, diagnosed* 1.9 1.9 0.001 
      Hypertension* 26.4 26.2 0.004 
      Malignant hypertension* 0.9 1.0 0.001 
      Hyperlipidemia* 28.6 28.3 0.006 
      Peripheral vascular disease* 1.7 1.7 0.001 
      Diabetes mellitus* 13.0 13.0 0.001 
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      Diabetes, ocular complication* 0.6 0.6 0.000 
      Diabetes, neurologic complication 0.8 0.8 0.002 
      Diabetes, skin complication* 0.3 0.3 0.002 
      Diabetes, renal complication* 0.4 0.4 0.001 
      Diabetes, other complication 0.7 0.7 0.002 
      Schizophrenia or other psychotic disorders 0.2 0.2 0.001 
      Alcohol abuse* 0.5 0.5 0.000 
      Bipolar disorder 1.1 1.0 0.002 
      Unipolar depression and/or anxiety disorder 16.0 15.9 0.003 
      Parkinson's Disease 0.1 0.1 0.002 
      Seizure disorder 0.8 0.8 0.002 
      Dementia* 0.1 0.1 0.000 
      Other cognitive disorders 0.2 0.2 0.001 
      Chronic lung disease* 9.5 9.7 0.007 
      COPD and other respiratory conditions* 1.9 2.0 0.004 
      Asthma* 7.0 7.2 0.006 
      Diagnosed smoking* 4.3 4.3 0.001 
      Rheumatic disease* 35.6 34.5 0.023 
      Chronic liver disease* 2.7 2.8 0.004 
      Chronic kidney disease* 1.4 1.5 0.002 
      Hypokalemia 0.3 0.3 0.001 
      Fluid and electrolyte disorders 0.3 0.3 0.001 
      Cardiac revascularization* 0.1 0.1 0.000 
Medication use history (%)    
      ACE inhibitor* 11.8 11.6 0.005 
      Anticoagulant* 1.9 1.8 0.005 
      Angiotensin receptor blocker* 6.8 6.8 0.002 
      Aspirin 0.4 0.4 0.001 
      Na+-channel blocker* 0.2 0.2 0.002 
      Beta-adrenergic blocker* 10.2 10.1 0.003 
      K+-channel blocker* 0.3 0.3 0.002 
      Ca2+-channel blocker* 6.8 6.7 0.000 
      Digoxin 0.3 0.3 0.002 
      Loop diuretic* 2.1 2.2 0.003 
      Other diuretic* 12.9 12.8 0.004 
      Insulin* 2.1 2.1 0.001 
      Oral antidiabetic 7.1 7.1 0.001 
      Statin* 17.7 17.6 0.003 
      Fibrate lipid-lowering agent* 2.2 2.2 0.000 
      Nitrate anti-anginal 0.9 0.9 0.002 
      Other antihypertensive* 2.4 2.5 0.007 
      Peripheral vasodilator* 0.2 0.2 0.001 
      Platelet inhibitor, not aspirin* 1.2 1.2 0.000 
      Tricyclic/tetracyclic antidepressant* 2.6 2.6 0.002 
      SSRI/SNRI antidepressant* 12.9 12.8 0.004 
      Trazodone antidepressant* 2.1 2.1 0.001 
      Other antidepressant* 3.4 3.4 0.000 
      Lithium antipsychotic* 0.2 0.2 0.001 
      Atypical antipsychotics* 1.3 1.3 0.001 
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      Other antipsychotics* 0.4 0.4 0.002 
      Benzodiazepine anticonvulsants* 7.3 7.2 0.004 
      GABA agonist anticonvulsant* 3.5 3.5 0.002 
      Hydroxyzine* 0.9 0.9 0.000 
      Adrenergic beta-agonist* 10.4 10.5 0.002 
      Other bronchodilator* 1.0 1.0 0.003 
Healthcare Utilization (%)    
      Any prescription (other than study ABX) past 30 
days* 
67.9 66.2 0.036 
      Any antibiotic use past 30 days* 8.6 8.3 0.008 
      Any outpatient visit past 30 days* 45.0 45.1 0.002 
      Any outpatient visits 30-365 days* 90.4 90.2 0.004 
      Any ED visit past 7 days 1.1 1.1 0.001 
      Any hospitalization past 30 days 0.4 0.4 0.003 
      Any hospitalization past 30-365 days* 8.6 8.5 0.000 
* Covariates included the propensity score model 
C-statistic: 0.602 
Hosmer and Lemeshow Goodness-of-Fit (GOF) test: χ2=167.4 (df = 8, p-value < 0.0001) 
ABX = antibiotics, ACE = angiotensin converting enzyme, AMO = amoxicillin, COPD = 
chronic obstructive pulmonary disease, ED = emergency department, FLQ = fluoroquinolone 
antibiotics, GABA = gamma-amino butyric acid 
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Appendix F. Sensitivity analysis 
 
Appendix Figure F.1 Cumulative incidence of ventricular arrhythmia and sudden death with 
azithromycin and amoxicillin in all diagnoses 
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Azithromycin
No. of events  Amoxicillin                52                                                                                       130 
                           Azithromycin            63                                                                                       129             
10 days follow-up 
Hazard Ratio 1.21, 95% CI 0.84–1.75, P=0.307 
 
30 days follow-up 
Hazard Ratio 0.99, 95% CI 0.78–1.27, P=0.950 
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Appendix Figure F.2 Cumulative incidence of ventricular arrhythmia and sudden death with 
fluoroquinolones and amoxicillin in all diagnoses 
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10 days follow-up 
Hazard Ratio: 0.87, 95% CI, 0.61–1.25, P=0.462 
 
30 days follow-up 
Hazard Ratio: 1.01, 95% CI, 0.80–1.27, P=0.952 
No. of events  Amoxicillin                63                                                                                       139 
                           Fluoroquinolones    55                                                                                       140 
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